ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[STARD13, TBXA2R, ROCK2, THBS1, GTF2I, CCR2]
GO:0036498;IRE1-mediated unfolded protein response;6.0;1.0;0.8231203125901445;9.628524252492122;55.46397693329154;5.825829909099042;0.0018563293936187412;0.6210535250702663;[ERN1, EXTL2, CTDSP2, EDEM1, LMNA, SYVN1, TPP1]
GO:0002480;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent;6.0;1.0;0.8231203125901445;9.628524252492122;33.24930607151726;7.57984905034425;0.0011128243517809471;0.710754145523778;[LNPEP, HLA-A, HLA-F]
GO:1901224;positive regulation of NIK/NF-kappaB signaling;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.82315740091596;5.572381008289503;0.007993196151321231;0.6599718239061428;[NLRP12, IL23A, SPHK1, ZFP91, TNFRSF10A, CCL19, RELA, LIMS1]
GO:1901223;negative regulation of NIK/NF-kappaB signaling;8.0;1.0;0.875;9.628524252492122;239.1998693179246;6.686031174322154;0.008005804360164796;0.7169239451870815;[NLRP12, NLRP3, RELA]
GO:0060368;regulation of Fc receptor mediated stimulatory signaling pathway;6.0;0.8436909121759173;0.7449657686781032;9.446202695698167;67.47621599979578;7.9853141584524145;0.0022583682248613433;0.7314896500084853;[CSK]
GO:1903527;positive regulation of membrane tubulation;7.0;1.0;0.8509193652572005;9.628524252492122;66.12399207475434;8.390779266560578;0.0022131105070127294;0.7800242071602487;[PLEKHM2]
GO:0000188;inactivation of MAPK activity;13.0;0.8436909121759173;0.8844004208555951;9.558319993818873;2610.871803759405;6.518977089658987;0.08738352963975493;0.7959357562962344;[PPP2CA, DUSP14]
GO:0002479;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent;6.0;1.0;0.8231203125901445;9.628524252492122;33.24930607151726;6.518977089658987;0.0011128243517809471;0.6565011041187423;[HLA-A, HLA-F, TAPBP]
GO:0071492;cellular response to UV-A;8.0;1.0;0.875;9.628524252492122;82.44278777713699;8.67846133901236;0.0027592859132088378;0.8188169164668168;[PPID]
GO:0048489;synaptic vesicle transport;7.0;0.7671156992804218;0.7344772148974115;9.292052015870908;108.01043080855717;5.459585514144159;0.003615011916085639;0.6301228223472235;[AP3M1, TRIM9, TOR1A, SYNJ1, SPG11, SYTL3]
GO:0000184;nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;10.0;0.8933024483968273;0.861892236059334;9.57851383191746;717.2549128915896;4.989581884898423;0.0240058764469685;0.6704084614939124;[UPF2, UPF1, RPS9, SMG1, RPL3, RPL23A, CASC3, SMG5, PPP2CA, SKIV2L, ETF1, DCP1A, DCP2, RPL19]
GO:0030705;cytoskeleton-dependent intracellular transport;5.0;0.5960880403619941;0.5882850320419173;7.885554947433499;33.20429938101479;4.695669262696007;0.0011113180183532213;0.5303777563261461;[IFT122, TRAK1, FNBP1L, DYNLL2, RAB21, FXR1, AP3M1, ARHGAP21, TUBA1C, SPAST, RHOT1, RAB6A, TNPO1, SPG11, CLUAP1, PAFAH1B1]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[NFKBIA, BCL3, TNPO1, TNPO2, KPNB1, IPO4, ARNTL]
GO:0071375;cellular response to peptide hormone stimulus;7.0;0.7369933605727446;0.7194160455435727;9.117698628726131;386.0268190343683;4.727217620430932;0.012919970231498398;0.5926694942041391;[RAP1B, ERRFI1, SP1, MAX, MARS, CSK, CRHR1, TSHR, NFKB1, RELA, RAB8B]
GO:0097527;necroptotic signaling pathway;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;7.9853141584524145;7.75488093814194E-4;0.6986103492792611;[RIPK1]
GO:2000352;negative regulation of endothelial cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;129.9263443150347;6.444869117505266;0.0043485178181058145;0.7258315315665724;[FGA, TNIP2, FGG]
GO:0051403;stress-activated MAPK cascade;10.0;0.811012628672052;0.8207473261969463;9.451593544333043;288.8226961090722;5.500407508664414;0.009666635715219814;0.696532107649126;[TNIP2, CCM2, NFKB1]
GO:0034067;protein localization to Golgi apparatus;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;32.77360880529348;6.686031174322154;0.001096903192380182;0.665044257777226;[RAB6A]
GO:0036120;cellular response to platelet-derived growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.781341354126479;0.003262744749111514;0.6699184248047958;[ERRFI1, MARS, ATP7A]
GO:0002374;cytokine secretion involved in immune response;10.0;1.0;0.9152410118609203;9.628524252492122;137.06961104194002;8.67846133901236;0.004587596526932657;0.8590579283277371;[NLRP3]
GO:0006974;cellular response to DNA damage stimulus;4.0;0.5696777571895439;0.534838878594772;7.469040003138749;28.997869804256865;3.161008442547652;9.705326059599744E-4;0.4116541187538124;[USP36, FEN1, BTG2, CDKN1A, SMG1, WDR48, DCLRE1C, CIB1, AATF, YY1, POLB, NIPBL, CHAF1A, CASP2, EP300, UPF1, AQR, TIPIN, FBXO18, DTX3L, NCOA6, RAD23A, TFIP11, DDB1, NEIL3, RAD51C, TFDP2, MSH3, DDIT4, TIMELESS, TANK, RAD51AP1, NUAK1, POLR2B, RBBP5, RAD21, POLR2G, USP51, BID, E2F7, E2F8, FANCI, UBE2B, EYA2, XRCC5, INTS3, GINS4, CNOT10, GTF2H4, SETX, CDK9, SMUG1, CNOT6, HIST3H2A, COPS5, CNOT1, UBE2T, BCL3, MNDA, CNOT8]
GO:0006612;protein targeting to membrane;10.0;0.811012628672052;0.8207473261969463;9.414950152194063;149.73401455281405;4.753193106834193;0.0050114627152184205;0.6583195283905053;[PEX16, TRAM1, RPS9, PEX19, RPL3, NCF1, SSR2, RAB3IP, ZDHHC23, ZDHHC24, RPL23A, CHMP4B, RAB8B, RPL19]
GO:0060236;regulation of mitotic spindle organization;9.0;0.7980440201809971;0.7952626352707877;9.360260265897443;71.51327617590798;6.193554689224359;0.0023934849958375417;0.7129793000169707;[STAG2, TPR, NUP62, CHMP4B, RAE1]
GO:0006610;ribosomal protein import into nucleus;10.0;1.0;0.9152410118609203;9.628524252492122;278.22868408041535;7.697632086000634;0.009312063666612497;0.8088982747154926;[TNPO1, TNPO2, KPNB1, IPO4]
GO:0051653;spindle localization;4.0;0.7866048967936545;0.6433024483968273;9.223059144383958;22.024791997814198;5.9928839937622085;7.371499671409332E-4;0.5564763661386056;[NSFL1C, ACTR2, ESPL1, KPNB1, CLASP1, NDC80, PAFAH1B1]
GO:0048011;neurotrophin TRK receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;58.19790639729547;6.781341354126479;0.0019478315524021762;0.7217981122146513;[DDIT4]
GO:0071480;cellular response to gamma radiation;7.0;1.0;0.8509193652572005;9.628524252492122;60.39874674087868;6.444869117505266;0.0020214916980741903;0.6805102716434839;[CDKN1A, XRCC5, ELK1]
GO:0048010;vascular endothelial growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.186691500213083;31.002284443533863;5.572381008289503;0.0010376185600805164;0.6599718239061428;[NCKAP1, NCF1, ROCK2, ITGB3, ELMO1, NCKAP1L, VAV1]
GO:0051893;regulation of focal adhesion assembly;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;59.47724087459839;5.769740442447999;0.0019906497260312257;0.6459841598043611;[SFRP1, ROCK2, THBS1, CLASP1, LIMS1]
GO:2000008;regulation of protein localization to cell surface;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;29.0551629072873;6.166155715036245;9.724501545579579E-4;0.6384578026126634;[FCER1G, TOR1A, TAX1BP3, LRIG2, ABCA12, TM9SF4]
GO:0071481;cellular response to X-ray;7.0;1.0;0.8509193652572005;9.628524252492122;60.39874674087868;7.379178354882098;0.0020214916980741903;0.728290889492758;[NIPBL, SFRP1, XRCC5]
GO:0030814;regulation of cAMP metabolic process;9.0;0.7140352122741334;0.7532582313173557;9.245532000236016;212.55514157362143;5.407625775213448;0.00711402930126111;0.6727868588050205;[TBL1XR1, CALM1, CALM2, CRHR1, TSHR, CCR2]
GO:0048015;phosphatidylinositol-mediated signaling;7.0;0.9326813400603323;0.8172600352873667;9.510741216835738;26.42836680105094;5.649939242635378;8.845336528452411E-4;0.6398575208746181;[C1QBP, PIK3C3, SIRT2, EXOC1]
GO:0006606;protein import into nucleus;9.0;0.8933024483968273;0.8428918493787028;9.551563211355994;277.5355368998559;5.288437257948329;0.009288864654271135;0.6666915524892495;[IPO8, NUP62, LMNA, HEATR3, NUP153, TNPO1, TNPO2, RGPD1, RAE1, KPNB1, IPO4]
GO:0072332;intrinsic apoptotic signaling pathway by p53 class mediator;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;80.0523555558605;5.734022359845919;0.002679280298012042;0.64415753539903;[CDKN1A, ZMAT1, BCL3, DDIT4, TP53BP2, EP300, KRCC1]
GO:0071363;cellular response to growth factor stimulus;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;60.394260804020476;4.247644540169047;0.0020213415578046274;0.5074657511808371;[TBX1, BECN1, ERRFI1, CAD, CIB1, LRP8, THBS1, RUNX2, SIRT2, RELA, SETX, ERN1, VIL1, SFRP1, CCL5, MARS, RIPK1, ATP7A, LIMS1]
GO:0006607;NLS-bearing protein import into nucleus;10.0;1.0;0.9152410118609203;9.628524252492122;278.22868408041535;6.481236761676141;0.009312063666612497;0.7466917612613706;[TNPO1, TNPO2, RGPD1, KPNB1, IPO4]
GO:0048013;ephrin receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;5.395046993006588;0.0010376185600805164;0.6509029541176994;[ACTR2, ARPC2, ROCK2, ARPC1A, EPHA1]
GO:0071364;cellular response to epidermal growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.088194173566533;0.003262744749111514;0.63447084575632;[VIL1, BECN1, ERRFI1, MARS, CAD]
GO:2001214;positive regulation of vasculogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;246.74152534447236;7.474488534686424;0.008258216800323579;0.7331650565203278;[HIF1AN]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[IGFBP5, C1QBP, CD80, CCL19, THBS1, VAV1, STK3, HBEGF]
GO:0035264;multicellular organism growth;3.0;1.0;0.6981203125901445;9.628524252492122;22.582921643529833;5.382624473008031;7.558300640989654E-4;0.47338797845741154;[WDR48, NDUFS6, TBL1XR1, H3F3A, TMED2, CCM2]
GO:0035022;positive regulation of Rac protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;338.93141114640116;8.67846133901236;0.01134372931260349;0.8590579283277371;[ALS2, KRAS]
GO:0035023;regulation of Rho protein signal transduction;9.0;0.8436909121759173;0.8180860812682478;9.318369324188282;48.758993290020136;4.879233827729558;0.0016319196251719597;0.645764870037956;[BCR, ABR, FLCN, AKAP13, ALS2, ARHGDIB, ECT2, ARHGEF5, VAV1]
GO:0035025;positive regulation of Rho protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;339.6245583269611;6.481236761676141;0.01136692832494487;0.7466917612613706;[AKAP13]
GO:0043928;exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay;11.0;0.9326813400603323;0.8987696223598284;9.60383163990175;718.8643508040237;6.280566066213989;0.024059742885497587;0.7536173930320365;[HBS1L, CNOT6, SKIV2L, CNOT8, LSM5, DCP1A, DCP2]
GO:1904876;negative regulation of DNA ligase activity;9.0;1.0;0.896240625180289;9.628524252492122;498.8744085339941;9.777073627680469;0.01669687749581391;0.896240625180289;[TFIP11]
GO:0000398;mRNA splicing, via spliceosome;11.0;0.8259837884571596;0.845420846558242;9.4949928598676;356.66873027722005;4.19357731889877;0.011937381421361158;0.6468886914394342;[SF3B5, SF3B2, WBP4, DDX42, DDX41, CASC3, USP39, EFTUD2, PABPN1, PCF11, U2AF2, POLR2B, SNRPB2, POLR2G, SMNDC1, RBM5, AQR, GPKOW, BUD31, CPSF2, TFIP11, LSM5, SRRM1, PRPF3, SNRPG, CD2BP2, SLU7]
GO:0002223;stimulatory C-type lectin receptor signaling pathway;11.0;1.0;0.9324289523296623;9.628524252492122;628.1099736002739;5.618190544320798;0.02102227555412486;0.7197434780388068;[CREBBP, FCER1G, EP300, KRAS, NFKB1, RELA]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[FGA, SERPINA3, WDR1, ITGB3, FGG, RAB27B, THBS1, LAMP2, CD9, PHACTR2, FAM3C, CALM1, ALDOA, A2M]
GO:0000045;autophagosome assembly;6.0;1.0;0.8231203125901445;9.628524252492122;62.10424204613046;5.769740442447999;0.0020785730910948433;0.618185107137305;[BECN1, NSFL1C, GABARAPL1, TP53INP2, TP53INP1, UBQLN1, PIK3C3]
GO:0071394;cellular response to testosterone stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;389.00028322827603;7.697632086000634;0.01301948940212445;0.7167775754447168;[ROCK2, ELK1]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[MAP3K3, OXTR, KSR1, IL5RA, GFRA2, SPTB, RASGRP4, NFKB1, SETX, KARS, PABPN1, PTPRA, TNIP2, CCL5, CTSH, NCAM1, CCM2, MBP, RIPK1, KRAS, CALM1, HBEGF]
GO:0071398;cellular response to fatty acid;6.0;0.7369933605727446;0.6916169928765168;9.004369943419128;203.00017448222317;5.8067817141283475;0.006794233151624104;0.6200793994936333;[SFRP1, GNG2, XRCC5]
GO:0071277;cellular response to calcium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;5.433268205826786;0.0026274528238337297;0.6009779013089371;[ECT2, ARID1A]
GO:0002218;activation of innate immune response;8.0;0.622025257344104;0.686012628672052;8.529911963824013;265.7077617868092;4.551326953967268;0.008892999665543976;0.6077550720842344;[COLEC12, FGA, CREBBP, FCER1G, XRCC5, ITGB2, FGG, NLRC4, TMEM173, LILRA2, TANK, NFKB1, RELA, NFKBIA, ITCH, TNIP2, EP300, RIPK1, PIK3C3, KRAS]
GO:0000281;mitotic cytokinesis;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;28.615093046006976;5.649939242635378;9.577214123380678E-4;0.5791791674783379;[PDCD6IP, SPAST, SON, ESPL1, CFL1, JTB, CHMP4B, ECT2]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[CDKN1A, ITGB2, PTX3, RIPK1, THBS1]
GO:2001240;negative regulation of extrinsic apoptotic signaling pathway in absence of ligand;10.0;1.0;0.9152410118609203;9.628524252492122;570.2036429558796;6.221725566191056;0.019084202779771145;0.7334203466557586;[EYA2, RIPK1]
GO:0034162;toll-like receptor 9 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;7.004484905440688;0.013811191226989502;0.8063299963962409;[TNIP2, PIK3C3]
GO:0036462;TRAIL-activated apoptotic signaling pathway;8.0;1.0;0.875;9.628524252492122;52.44533375847466;8.67846133901236;0.0017552981231601008;0.8188169164668168;[TNFRSF10A]
GO:0150033;negative regulation of protein localization to lysosome;7.0;1.0;0.8509193652572005;9.628524252492122;73.78875676133134;9.777073627680469;0.0024696432832320894;0.8509193652572005;[ROCK2]
GO:1901017;negative regulation of potassium ion transmembrane transporter activity;10.0;0.7866048967936545;0.8085434602577476;9.418803721510052;728.707892328508;7.004484905440688;0.024389197361709854;0.7734506956670166;[OXSR1]
GO:1900169;regulation of glucocorticoid mediated signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;41.8512380110395;9.083926447120524;0.0014007232725606145;0.7876727335416686;[AKAP13]
GO:1904528;positive regulation of microtubule binding;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;48.10964489978194;7.9853141584524145;0.0016101865189262975;0.7314896500084853;[PPP2CA, MAPRE1]
GO:0002476;antigen processing and presentation of endogenous peptide antigen via MHC class Ib;5.0;0.8653626801206646;0.7229223519212526;9.405380701177911;42.20009821028515;7.697632086000634;0.0014123993094755708;0.6838982747154925;[HLA-A, HLA-F]
GO:0072594;establishment of protein localization to organelle;6.0;0.6181399273706679;0.6321902762754785;8.242229891372231;52.25076648131265;3.8109268885567773;0.0017487861314926694;0.5180112908971621;[RPL3, HSD17B4, RGPD1, IPO4, AP3M1, NIPBL, IPO8, NUP62, LMNA, LAMP2, HEATR3, BID, TNPO1, TNPO2, RAE1, RAB8B, RPL19, PEX16, GSTK1, RPS9, PEX19, IFT122, NUP153, RPL23A, TIMM44, RAB11A, ACOX2, VPS41, AGPS, TSPAN17, CHMP4B, RAB3GAP2, KPNB1, ACOT4, RAB3GAP1]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[MTPN, BAG3, ITGA2, NPPA, CASP2, TNFRSF10A, NFKB1]
GO:0023035;CD40 signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;9.083926447120524;8.87013979980389E-4;0.7876727335416686;[TNIP2]
GO:0000290;deadenylation-dependent decapping of nuclear-transcribed mRNA;10.0;1.0;0.9152410118609203;9.628524252492122;717.2549128915896;7.474488534686424;0.0240058764469685;0.7974867031240476;[PAN3, DCP1A, DCP2]
GO:2001237;negative regulation of extrinsic apoptotic signaling pathway;9.0;0.8436909121759173;0.8180860812682478;9.50592193039979;358.6811287979994;5.152100814396198;0.012004734588810557;0.6597193004257005;[FGA, EYA2, FGG, LMNA, RIPK1, TNFRSF10A, RFFL, THBS1, RELA]
GO:2001238;positive regulation of extrinsic apoptotic signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.54514264355307;358.11284317915005;5.8650506222523235;0.011985714580571521;0.6961795867550195;[SFRP1, G0S2, RIPK1, BID, THBS1, STK3]
GO:2001235;positive regulation of apoptotic signaling pathway;8.0;0.6997970393407541;0.724898519670377;9.176539128749065;291.4603159253591;4.6590798152637145;0.009754914476767216;0.6132655584219551;[HRK, FBXO18, ATPIF1, PLAUR, G0S2, YWHAZ, THBS1, BBC3, STK3, SFRP1, TFDP2, TP53INP1, TP53BP2, CASP2, CTSH, RIPK1, SERINC3, BID]
GO:0016569;covalent chromatin modification;5.0;0.5374962537808747;0.5589891387513577;7.383097573338024;32.63830298611046;3.836902374960038;0.001092374628379458;0.4864603777505843;[SETD5, USP36, HDAC3, HDAC1, ARID4A, CHD1, RLF, RBBP5, ZNF407, EP300, USP51, SUDS3, RNF20, ZNF462, DR1, CREBBP, UBE2B, DTX3L, EYA2, SIRT2, POLE4, DDB1, PER2, TBL1XR1, EZH2]
GO:0060441;epithelial tube branching involved in lung morphogenesis;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;53.5045405888233;7.004484905440688;0.0017907488225476112;0.7091290490632969;[KRAS]
GO:0006886;intracellular protein transport;8.0;0.5537205960740763;0.6518602980370382;8.117066748418225;90.55259897265384;3.0436717358431102;0.0030307139955665606;0.5306535141162272;[RAB3B, ARF3, TRAM1, AHCYL1, RPL3, NCF1, CLTA, IPO4, RAB43, IPO8, AP1G1, NUP62, LAMP2, TMED2, TMED1, ARFIP1, EVI5L, TNPO1, TNPO2, TBC1D22A, RAB8B, VPS18, GSTK1, GRIPAP1, TMED9, RPS9, SSR2, COG3, TBC1D8, SYTL3, BCR, ACOX2, AGPS, CHMP4B, SLU7, KPNB1, ACOT4, COPB2, COPA, RABGAP1, ZDHHC23, HSD17B4, ZDHHC24, DERL2, VPS26B, TRAK1, RGPD1, NAPG, STX11, ARNTL, RAB21, AP3M1, RAB20, GGA3, LMNA, VPS11, HEATR3, STX5, BID, RAB6A, RAE1, RPL19, VPS16, PEX16, PEX19, RAB3IP, SYVN1, NUP153, RAB27B, RPL23A, TIMM44, RAB11A, ARCN1, NFKBIA, PAN3, SNX17, VPS41, BCL3, RAB18, RAB3GAP2, SEC24C]
GO:0006887;exocytosis;6.0;0.6696747006330769;0.657957662906683;8.375761283996754;37.082880499217325;3.1596706497059923;0.0012411306378830758;0.4847060165558207;[SERPINA3, SIGLEC9, WDR1, ITGB3, ITGB2, ABCA12, TRIM9, HK3, PSMD7, PSMD2, LAMP2, PHACTR2, CTSH, FAM3C, GUSB, SNAP29, FGA, ACTR2, SERPINB1, FCER1G, FGG, PLAUR, COMMD3, RNASE3, TMEM173, UNC13D, SYTL3, SERPINB6, VAMP4, DOCK2, ALDOA, VAMP5, KPNB1, EXOC1, CSTB, PDXK, CLEC12A, UBR4, IQGAP2, THBS1, STX11, C3, RAP1B, CCL5, PSMB1, NCKAP1L, A2M, RAB6A, TMEM30A, XRCC5, HSPA6, RAB27B, LILRB3, NFKB1, RAB11A, COPS5, SNX19, IMPDH2, VPS41, RAB18, CD9, PTX3, MNDA, DEGS1, CALM1]
GO:0002037;negative regulation of L-glutamate import across plasma membrane;11.0;0.9326813400603323;0.8987696223598284;9.601125278304007;766.7287507341721;9.777073627680469;0.02566172127599639;0.9324289523296623;[ARL6IP5]
GO:0050872;white fat cell differentiation;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;21.75937296335754;7.292166977892469;7.282666309192915E-4;0.6631627702307852;[PER2, TBL1XR1]
GO:0030866;cortical actin cytoskeleton organization;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;53.946853691669205;6.088194173566533;0.0018055526440439148;0.63447084575632;[VIL1, NCKAP1, PDCD6IP, EPB41, ROCK2, WIPF2, NCKAP1L]
GO:0045292;mRNA cis splicing, via spliceosome;12.0;1.0;0.9481203125901445;9.628524252492122;357.76734256588776;6.444869117505266;0.011974150985975996;0.7777112189764279;[WBP4]
GO:0006636;unsaturated fatty acid biosynthetic process;9.0;0.7508913569872202;0.7716863036738992;9.34084218004034;458.36729553176707;6.343086423195323;0.01534114087766428;0.7206263598461826;[ELOVL5, DEGS1, FADS1]
GO:0050871;positive regulation of B cell activation;8.0;0.7436939687323844;0.7468469843661922;9.117698628726131;160.32529438548238;4.695669262696007;0.00536594331968482;0.6151367444652258;[CDKN1A, IL6, TFRC, TNIP2, NCKAP1L]
GO:0051607;defense response to virus;6.0;0.8653626801206646;0.7558016526504768;9.485423408851448;78.89111305633469;4.573066940603674;0.0026404145566033123;0.5569871686019774;[IFNAR2, BECN1, APOBEC3F, DTX3L, APOBEC3H, DDX41, ZC3HAV1, TMEM173, LYST, UNC13D, RELA, ITCH, ILF3, IL6, POLR3C, IL23A, POLR3E, DDIT4, NLRP3, SERINC3, EXOC1]
GO:0016575;histone deacetylation;9.0;0.7866048967936545;0.7895430735771163;9.396722638434797;357.60632662761185;5.682729065458369;0.011968761927426838;0.6868556538617572;[PER2, HDAC3, HDAC1, TBL1XR1, ARID4A, SUDS3, SIRT2]
GO:0051603;proteolysis involved in cellular protein catabolic process;6.0;0.6519675769143192;0.6491041010473041;8.270400768338927;49.64990487012002;3.4509241545253704;0.001661737633989536;0.49960073433695684;[USP36, PPP1R11, USP32, CCNF, OTUD7B, UBE2Z, UBE2L3, PSMD8, TRIM9, PSMD7, PSMD4, PSMD2, CDC26, CTSH, SKP2, C18orf25, USP46, PDCD6IP, FBXO18, DTX3L, RAD23A, TRPC4AP, KCTD5, SIRT2, DDB1, PSMA1, KCTD10, TBL1XR1, CHMP4B, ANAPC5, MAN1B1, USP41, RNF38, USP12, UBR4, DERL2, NEDD8, PSMB10, PSMA7, ANAPC11, ARNTL, RNF213, TP53INP2, UBD, PSMB1, UBQLN1, USP51, RFFL, RNF20, UBE2I, TOR1A, LRRC29, UBE2B, KLHL25, EDEM1, SYVN1, FBXL15, ERLIN2, FBXL16, KBTBD4, NSFL1C, ITCH, FAP, PSMC1, FBXL3, TRIM32, MAD2L1]
GO:2001020;regulation of response to DNA damage stimulus;6.0;0.5902001590945054;0.6182203921373972;8.01908634005802;29.43425144606613;4.530049555519983;9.851379067933503E-4;0.5547872575282844;[SMG1, FBXO18, DTX3L, EYA2, WRNIP1, TFIP11, DEK, SENP2, CDK9, RAD51AP1, TIMELESS, USP51, BID, TRIM32, ZNF365]
GO:0036289;peptidyl-serine autophosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.585964638073326;523.0454128613271;7.697632086000634;0.017505859258158146;0.8088982747154926;[ERN1, RIPK1]
GO:0060674;placenta blood vessel development;4.0;0.9326813400603323;0.7163406700301662;9.474373572664863;32.95974767671161;6.343086423195323;0.0011031330928924386;0.5743857346658935;[TMED2, ARID1A]
GO:0014032;neural crest cell development;5.0;0.8933024483968273;0.736892236059334;9.510741216835738;64.99956039719687;6.558197802812269;0.002175476790687691;0.6256275524841266;[SOX8, KLHL12]
GO:0035196;production of miRNAs involved in gene silencing by miRNA;10.0;1.0;0.9152410118609203;9.628524252492122;119.55896959962375;7.069023426578259;0.004001531116412497;0.7767511986393403;[ZC3H7A, SNIP1]
GO:1901673;regulation of mitotic spindle assembly;10.0;1.0;0.9152410118609203;9.628524252492122;218.77880646863287;6.832634648514029;0.0073223297643623805;0.7646622655359331;[STAG2, TPR, CHMP4B]
GO:1901796;regulation of signal transduction by p53 class mediator;7.0;0.7192862368539868;0.710562483684194;9.117698628726131;45.070113835906206;4.948759890378168;0.001508456149618737;0.6039991761920099;[NUAK1, TBP, CSNK2A1, TP53INP1, TRIM24, TP53BP2, EP300, TAF7, SENP2, RFFL]
GO:0006893;Golgi to plasma membrane transport;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;32.11060110714162;5.845247994956144;0.0010747129213912287;0.6498456195510879;[BBS2, ARF3, SYS1, VAMP5, EXOC1]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[COLEC12, CD163L1, TFRC, WIPF2, ITGB3, ITGB2, STON1, CLTA, FNBP1L, RABEPK, LRP8, TM9SF4, KIAA1109, APOL1, SCARF1, FCER1G, AMBP, FNBP1, UNC13D, RUFY1, SYNJ1, SNX17, CD9, PIK3C3, DOCK2]
GO:0006895;Golgi to endosome transport;7.0;1.0;0.8509193652572005;9.628524252492122;52.5351401021073;6.8867018697843045;0.0017583038606610233;0.7031056191423581;[TGOLN2, SYS1]
GO:1904825;protein localization to microtubule plus-end;10.0;0.9326813400603323;0.8815816818910864;9.548481544818586;37.784244099391444;8.67846133901236;0.0012646046463946437;0.8590579283277371;[MAPRE1]
GO:0048208;COPII vesicle coating;6.0;1.0;0.8231203125901445;9.628524252492122;62.43707956725794;5.6339389012889365;0.0020897128633926582;0.6112402100070131;[TRAPPC2, TRAPPC3, PPP6C, TFG, TRAPPC6B, TMED2, STX5, KLHL12, SEC24C]
GO:0061646;positive regulation of glutamate neurotransmitter secretion in response to membrane depolarization;11.0;1.0;0.9324289523296623;9.628524252492122;1158.8257769644995;9.777073627680469;0.03878485587951174;0.9324289523296623;[RAB3GAP1]
GO:0030855;epithelial cell differentiation;4.0;0.5489353771682173;0.5244676885841086;6.961296045910167;21.066225782797595;4.034070439870987;7.050676185779127E-4;0.45630254989846264;[TBX1, GSTK1, CSTA, HDAC1, ITGA2, VIL1, RXRA, LBH, NFIB, CCM2, TPP1, E2F7, E2F8]
GO:0006406;mRNA export from nucleus;9.0;0.8933024483968273;0.8428918493787028;9.523163736834295;121.36021434248079;5.132682728539097;0.004061817156940898;0.658726258611935;[UPF2, UPF1, SMG1, SEH1L, CPSF2, NUP153, THOC2, CASC3, SMG5, SRRM1, ALKBH5, NXF3, PABPN1, U2AF2, TPR, NUP62, NUP43, SLU7, RAE1]
GO:0051973;positive regulation of telomerase activity;9.0;0.9326813400603323;0.8625812952104552;9.600353375525426;952.4250073221435;6.193554689224359;0.031876807868214944;0.7129793000169707;[XRCC5]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[TRAPPC2, DCTN5, TRAPPC3, COPB2, TMED9, COPA, DCTN4, COG3, GOSR1, COG1, KLHL12, DYNLL2, SPTB, ARCN1, RAB43, SPAST, TFG, TRAPPC6B, GOLGB1, TMED2, STX5, TMED1, SEC24C]
GO:1903608;protein localization to cytoplasmic stress granule;6.0;1.0;0.8231203125901445;9.628524252492122;32.77360880529348;7.8311634786251565;0.001096903192380182;0.7236063770733796;[DCP1A]
GO:0071320;cellular response to cAMP;7.0;1.0;0.8509193652572005;9.628524252492122;327.37290077043656;5.825829909099042;0.01095687637230394;0.6488525777373224;[RAP1B, IGFBP5, ITPR2]
GO:0070478;nuclear-transcribed mRNA catabolic process, 3'-5' exonucleolytic nonsense-mediated decay;12.0;1.0;0.9481203125901445;9.628524252492122;2155.676761680197;9.777073627680469;0.07214856123030505;0.9481203125901445;[SKIV2L]
GO:0050769;positive regulation of neurogenesis;7.0;0.5833093054345528;0.642574017974477;8.424551448166186;270.7084826640249;3.7179504320986725;0.009060369292947784;0.5410555232571033;[FOXG1, TRAK1, LRP8, CYB5D2, RELA, RAB21, PPP1CC, NIPBL, DVL3, SOX8, ECT2, SCARF1, MARK2, ZNF365, CCR2, ACTR2, TMEM30A, XRCC5, RAB11A, SETX, SYNJ1, FES, RUFY3, CAMK1, ADNP, TRIM32, PAFAH1B1, EZH2]
GO:0014029;neural crest formation;6.0;1.0;0.8231203125901445;9.628524252492122;35.87688261436843;7.8311634786251565;0.0012007669740048141;0.7236063770733796;[KLHL12]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[BBS2, RAB3B, GRIPAP1, SYS1, FCER1G, ROCK2, ZDHHC23, ABCA12, RAB11A, SLMAP, TMED2, VAMP5, RAB8B]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[PPP1R11, CCNF, UBE2Z, UBE2L3, TRIM9, NPEPPS, HERC4, HERC1, CDC26, TRIM24, TRIM69, SKP2, C18orf25, FBXO18, DTX3L, ZFP91, TRPC4AP, DDB1, KCTD10, ANAPC5, HIST1H2BC, HIST1H2BO, HIST1H2BJ, RNF38, UBR4, NEDD8, DTX2, KLHL12, NLRC4, ANAPC11, VCPIP1, RNF213, UBD, HLTF, RFFL, RNF20, UBE2I, UBE2B, KLHL25, SYVN1, FBXL15, LNPEP, FBXL16, ITCH, UBE2T, TSPAN17, KBTBD2, FBXL3, TRIM32]
GO:0050765;negative regulation of phagocytosis;8.0;0.8436909121759173;0.7968454560879586;9.503361109538115;175.4194889364855;7.069023426578259;0.005871132427413739;0.7365101867784198;[CSK]
GO:2001032;regulation of double-strand break repair via nonhomologous end joining;9.0;0.8933024483968273;0.8428918493787028;9.517298617381897;108.73467314569157;7.069023426578259;0.003639251655333741;0.757750811958709;[DTX3L, USP51, TFIP11, DEK]
GO:2001033;negative regulation of double-strand break repair via nonhomologous end joining;10.0;1.0;0.9152410118609203;9.628524252492122;721.4986092709557;7.9853141584524145;0.024147909145707098;0.8236103492792612;[TFIP11]
GO:1902895;positive regulation of pri-miRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1721.2385553242598;6.599019797332524;0.0576083054325737;0.7855944919115336;[RELA]
GO:1904837;beta-catenin-TCF complex assembly;5.0;1.0;0.7902410118609202;9.628524252492122;40.42272244673708;6.409777797693995;0.0013529121422039536;0.618037346520142;[TLE4, CREBBP, HDAC1, RBBP5, EP300]
GO:0006620;posttranslational protein targeting to endoplasmic reticulum membrane;11.0;1.0;0.9324289523296623;9.628524252492122;336.65241395888097;7.57984905034425;0.011267453327701498;0.8200627852632958;[CHMP4B]
GO:1900119;positive regulation of execution phase of apoptosis;8.0;0.8436909121759173;0.7968454560879586;9.420884887713877;104.73281067498594;7.292166977892469;0.0035053129198816214;0.747921758369865;[FAP, TP53BP2, SIRT2]
GO:0070262;peptidyl-serine dephosphorylation;8.0;1.0;0.875;9.628524252492122;179.24922260518233;7.292166977892469;0.005999310166768488;0.747921758369865;[PPP2CA]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[CDKN1A, CEP70, FBXL15, SKP2, MAPRE1, CKAP5, CLASP1, PAFAH1B1]
GO:0071475;cellular hyperosmotic salinity response;7.0;0.9326813400603323;0.8172600352873667;9.567899630675686;243.83975882422638;8.390779266560578;0.008161097286311265;0.7800242071602487;[XRCC5]
GO:0071354;cellular response to interleukin-6;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.004484905440688;0.0027327542132076126;0.6813299963962409;[ABCC2, FGG, NFKB1, RELA]
GO:0045199;maintenance of epithelial cell apical/basal polarity;6.0;1.0;0.8231203125901445;9.628524252492122;34.60247581110787;7.138016298065211;0.001158113725191344;0.6881587980249038;[PDCD6IP, WDR1]
GO:0071476;cellular hypotonic response;6.0;0.8933024483968273;0.7697715367885581;9.474373572664863;99.28236748284083;7.8311634786251565;0.003322891491320933;0.7236063770733796;[OXSR1]
GO:0072321;chaperone-mediated protein transport;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;57.348299591639034;7.474488534686424;0.0019193959772133386;0.7572456912631272;[PEX19, TOR1A]
GO:0000082;G1/S transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;42.752976916212816;5.142344639450834;0.0014309036622044387;0.5532207558659172;[POLE4, PPP6C, CDKN1A, GPR132, MAX, GMNN, SKP2, MCM2]
GO:0071359;cellular response to dsRNA;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;141.5689593603356;6.781341354126479;0.004738185665998763;0.6699184248047958;[COLEC12, TMEM173, NFKB1]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[SFRP1, ABCC2, CCL20, CCL5, CIB1, RORA, RIPK1, CCL19, THBS1, TANK, NFKB1, RELA]
GO:0045070;positive regulation of viral genome replication;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;85.31211810933421;6.221725566191056;0.0028553198171978322;0.6931793347948383;[DDB1, CCL5, RAD23A, PPID]
GO:0045071;negative regulation of viral genome replication;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;85.23964546052278;5.8067817141283475;0.0028528942228632634;0.6719590869034888;[ILF3, APOBEC3F, APOBEC3H, CCL5, ZC3HAV1]
GO:0050776;regulation of immune response;4.0;0.37937792944451876;0.4396889647222594;5.635843344046521;22.446924158408432;2.846578861728843;7.512783506617425E-4;0.39557417536826767;[NCKAP1, CUEDC2, SIGLEC9, TFRC, WIPF2, GFI1, C12orf4, CD80, ITGB2, ARPC1A, AP1G1, C1QBP, NPPA, EP300, CTSH, CCR2, HLA-DPA1, IFNAR2, FGA, ACTR2, IL4R, FCER1G, PVRIG, FGG, HLA-A, TMEM173, HLA-F, UNC13D, VAV1, BCR, KARS, CD8B, IL23A, ELMO1, PIK3C3, LCP2, ANKRD17, COLEC12, CFH, NLRC4, LILRA2, SUPT6H, TANK, RELA, C2, C3, ABR, HLA-DMB, CCL5, UBQLN1, SLAMF7, NLRP3, NCKAP1L, RIPK1, CSK, CCL19, A2M, HLA-DQA1, CREBBP, AMBP, BTN2A1, XRCC5, PILRB, PILRA, NFKB1, NFKBIA, ITCH, CD4, IL6, COL1A2, ARPC2, POLR3C, FES, TNIP2, HLA-DPB1, MNDA, KRAS, CALM1, HLA-DRB3, C1QC]
GO:0042921;glucocorticoid receptor signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;54.70458253798286;7.8311634786251565;0.0018309131466183446;0.7967266896635242;[NCOA6, ARID1A]
GO:0060333;interferon-gamma-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.514393750639154;0.00101047745553359;0.6329257181104212;[CIITA, HLA-DPB1, NCAM1, HLA-A, HLA-DRB3, HLA-F, HLA-DQA1, HLA-DPA1]
GO:1900364;negative regulation of mRNA polyadenylation;11.0;1.0;0.9324289523296623;9.628524252492122;727.4995684895773;7.697632086000634;0.024348755850241696;0.8260862151842345;[CDK9, RNF20]
GO:1900244;positive regulation of synaptic vesicle endocytosis;8.0;0.9326813400603323;0.8413406700301662;9.577230958104572;265.8961164942356;7.9853141584524145;0.008899303728093307;0.7833693374183408;[TOR1A]
GO:0060218;hematopoietic stem cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;45.53364894725875;7.379178354882098;0.0015239702526411902;0.6676125360964777;[SFRP1, XRCC5, HOXB4]
GO:0061428;negative regulation of transcription from RNA polymerase II promoter in response to hypoxia;13.0;1.0;0.9625549647676366;9.628524252492122;2908.113696527873;8.390779266560578;0.09733194829037965;0.8916598066706847;[HIF1AN, SIRT2]
GO:1901215;negative regulation of neuron death;6.0;0.7586651285174919;0.7024528768488905;9.05316010758856;58.54459561550999;4.545965010825883;0.001959434928535777;0.5556011746527726;[BTG2, PSMC1, CHMP4B, KRAS, ADNP, SNCB, CPEB4]
GO:0006633;fatty acid biosynthetic process;8.0;0.6493065804076676;0.6996532902038338;8.912904216080118;359.8485513982277;5.076593261888053;0.01204380717262807;0.6346172154986847;[ELOVL5, DEGS1, HSD17B8, PRKAB1, FADS1, MGLL]
GO:1901216;positive regulation of neuron death;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;58.38287487682085;5.370354380416217;0.001954022280951067;0.5977604853516485;[TFAP2A, ITGB2, DDIT4, TP53BP2, CASP2, ELK1]
GO:0006513;protein monoubiquitination;10.0;0.8653626801206646;0.8479223519212526;9.574457031221845;155.4032479663248;5.649939242635378;0.005201206855589802;0.704179167478338;[DDB1, RNF20, UBE2B, DTX3L, UBE2T, KLHL12]
GO:1900127;positive regulation of hyaluronan biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;589.7686013946351;8.390779266560578;0.019739024331396862;0.8253454670833372;[NFKB1]
GO:0006511;ubiquitin-dependent protein catabolic process;8.0;0.7369933605727446;0.7434966802863723;9.190269321560967;156.4521708431119;3.582668236575797;0.005236313360306564;0.5582178202295975;[USP36, PPP1R11, USP32, CCNF, UBE2Z, UBE2L3, PSMD8, TRIM9, PSMD7, PSMD4, PSMD2, CDC26, SKP2, C18orf25, USP46, FBXO18, DTX3L, RAD23A, TRPC4AP, KCTD5, SIRT2, DDB1, PSMA1, KCTD10, TBL1XR1, ANAPC5, MAN1B1, USP41, RNF38, USP12, UBR4, DERL2, NEDD8, PSMB10, PSMA7, ANAPC11, ARNTL, RNF213, TP53INP2, UBD, PSMB1, UBQLN1, USP51, RFFL, RNF20, UBE2I, LRRC29, UBE2B, KLHL25, EDEM1, SYVN1, FBXL15, ERLIN2, FBXL16, KBTBD4, NSFL1C, ITCH, PSMC1, FBXL3, TRIM32, MAD2L1]
GO:0060337;type I interferon signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.587418885654044;0.00101047745553359;0.6366602269110988;[IFNAR2, HLA-A, HLA-F]
GO:0090090;negative regulation of canonical Wnt signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;236.99226377157444;4.932886541221878;0.00793191778924446;0.6272680471207706;[TLE4, SFRP1, HDAC1, DVL3, KLHL12, DACT1, STK3]
GO:0070371;ERK1 and ERK2 cascade;10.0;1.0;0.9152410118609203;9.628524252492122;233.3964595037646;6.481236761676141;0.007811569456414605;0.7466917612613706;[OXTR, KARS, CTSH]
GO:0050663;cytokine secretion;9.0;0.6056485694559711;0.6990649099082746;8.227631091951078;133.331941423656;5.9928839937622085;0.004462500088492957;0.7027169913188946;[NLRP3, LCP2, NLRC4, CCL19]
GO:0030953;astral microtubule organization;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;97.68103242922432;7.8311634786251565;0.0032692962481843716;0.7514054297404357;[KPNB1, CLASP1, RAB11A]
GO:0045083;negative regulation of interleukin-12 biosynthetic process;8.0;1.0;0.875;9.628524252492122;836.0204953067102;9.777073627680469;0.027980853608317785;0.875;[NFKB1]
GO:0045084;positive regulation of interleukin-12 biosynthetic process;8.0;1.0;0.875;9.628524252492122;834.8798377098682;8.16763571524637;0.027942676825076673;0.7926932703116032;[RELA]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[UPF1, ABCC2, CCL20, GFI1, CD80, PDCD1LG2, NFKB1, RELA, BCR, IL6, PABPN1, NLRP7, TBXA2R, TNIP2, NLRP3]
GO:0030836;positive regulation of actin filament depolymerization;11.0;0.8259837884571596;0.845420846558242;9.503361109538115;392.2090701602175;7.212124270218933;0.013126884613015779;0.8012573229067359;[VIL1, WDR1, CFL1]
GO:0071223;cellular response to lipoteichoic acid;6.0;1.0;0.8231203125901445;9.628524252492122;155.87545856417063;7.474488534686424;0.005217011319337755;0.7053660038532718;[CCL20, RELA]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[ANKRD17, COLEC12, HIST1H2BJ, NCF1, CFH, DEFB1, NLRC4, ZC3HAV1, LILRA2, LYST, RELA, C2, C3, PPP6C, PRDX1, C1QBP, SLAMF7, NLRP3, CSK, APOL1, FGA, APOBEC3F, FCER1G, DTX3L, APOBEC3H, XRCC5, WRNIP1, RNASE3, TMEM173, SIRT2, NFKB1, ITCH, POLR3C, IL23A, FES, ELF4, POLR3E, TRIM14, PTX3, SERINC3, TRIM32, CD244, C1QC, HIST1H2BC]
GO:0097711;ciliary basal body-plasma membrane docking;5.0;1.0;0.7902410118609202;9.628524252492122;21.38880323109876;5.223196736079928;7.158639954716971E-4;0.5573555358475362;[CEP70, RAB3IP, MAPRE1, CKAP5, CLASP1, RAB11A, PAFAH1B1]
GO:0070373;negative regulation of ERK1 and ERK2 cascade;11.0;1.0;0.9324289523296623;9.628524252492122;1180.902522994834;5.6339389012889365;0.039523744701365535;0.7205488497465309;[FLCN, ERRFI1, NLRP12, CSK]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[RAP1B, FGA, CD4, KARS, CCL20, CCL5, FGG, CIB1, CCL19, EPHA1]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[CCNF, UBE2Z, UBE2L3, YY1, PSMD8, NPEPPS, PSMD7, PSMD4, PSMD2, CDC26, SKP2, C18orf25, FBXO18, TRPC4AP, KCTD5, SFRP1, KCTD10, TBL1XR1, PSME2, CHMP4B, ANAPC5, UBR4, ANAPC11, C2, C3, VCPIP1, RHOT1, RNF213, UBD, NLRP3, USP51, RIPK1, UBE2I, TOR1A, UBE2B, KLHL25, EDEM1, LNPEP, ERLIN2, PGA3, PGA5, NFKB1, NFKBIA, NSFL1C, COPS5, FBXL3, TPP1, USP36, WDR48, PPP1R11, USP32, OTUD7B, USP39, SENP6, POLB, TRIM9, CASP2, CTSH, CTSE, USP46, FGA, PDCD6IP, DTX3L, RHBDF2, FGG, RAD23A, SENP2, JOSD1, SIRT2, DDB1, PSMA1, ESPL1, PIK3C3, MAN1B1, USP41, BECN1, RNF38, USP12, DERL2, NEDD8, LRP8, TANK, PARL, PSMB10, PSMA7, RELA, ARNTL, TP53INP2, PSMB1, ADAM23, UBQLN1, RFFL, SEC11A, RNF20, LRRC29, SYVN1, FBXL15, FBXL16, CAPN13, KBTBD4, ITCH, XPNPEP1, FAP, TNIP2, PSMC1, TRIM32, C1QC, MAD2L1]
GO:0071347;cellular response to interleukin-1;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.446340287394138;0.0027327542132076126;0.6016464081682054;[UPF1, ABCC2, CCL20, FGG, RORA, TANK, NFKB1, RELA, YY1, SFRP1, NLRP7, CCL5, CCL19]
GO:0071224;cellular response to peptidoglycan;6.0;1.0;0.8231203125901445;9.628524252492122;318.29655603595194;8.16763571524637;0.010653099282220678;0.7408135829017477;[NLRP3, RELA]
GO:0070498;interleukin-1-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.845247994956144;0.00101047745553359;0.6498456195510879;[NFKBIA, MAP3K3, TNIP2, NFKB1, RELA]
GO:0071346;cellular response to interferon-gamma;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[RAB43, ACTR2, RAB20, CCL20, CCL5, VPS26B, CCL19, HLA-DPA1]
GO:0036258;multivesicular body assembly;7.0;1.0;0.8509193652572005;9.628524252492122;62.72328125453724;6.375876246018314;0.0020992917763011008;0.6769819729871445;[PDCD6IP, CHMP4B, CHMP6, RAB11A]
GO:0036138;peptidyl-histidine hydroxylation;9.0;1.0;0.896240625180289;9.628524252492122;310.64229491696193;9.777073627680469;0.010396918050955857;0.896240625180289;[HIF1AN]
GO:0019932;second-messenger-mediated signaling;6.0;0.6547035408479693;0.6504720830141292;8.316337863525954;26.42836680105094;4.103750360508977;8.845336528452411E-4;0.5329862968704817;[MCTP1, KSR1, CCL20, SPHK1, EIF2AK3, ITPR2, DEFB1, CRHR1, TSHR, PPP2CA, AKAP13, GNG2, GAL, TBXA2R, GNAQ, RCAN3, NMUR1, CALM1, CALM2, CCR2]
GO:0090611;ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway;7.0;1.0;0.8509193652572005;9.628524252492122;51.84712944745551;8.16763571524637;0.001735276763219217;0.7686126355688037;[PDCD6IP, CHMP4B]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[RAB3B, AHCYL1, SYS1, RPL3, TFRC, NCF1, IPO4, RAB43, EIF4ENIF1, IPO8, LAMP2, ARFIP1, TBC1D22A, VPS18, GSTK1, RPS9, VPS33B, COG3, COG1, SYTL3, BCR, RUFY1, CHMP4B, KPNB1, ACOT4, PPID, COPB2, COPA, SUCNR1, VPS26B, VPS8, VPS11, NLRP3, ECT2, RAB6A, ATP6V1F, VPS16, BBS2, TOR1A, RAB3IP, NUP153, RAB27B, TIMM44, NFKBIA, PAN3, BCL3, ARF3, TRAM1, AHCTF1, SFT2D3, CLTA, LYST, AP1G1, NUP62, TMED2, TMED1, EVI5L, TNPO1, TNPO2, SNAP29, RAB8B, GRIPAP1, TMED9, PDCD6IP, DTX3L, SSR2, RHBDF2, FGG, TBC1D8, SENP2, AFTPH, GAL, ACOX2, AGPS, LCP2, CHMP6, SLU7, VAMP5, PAFAH1B1, EXOC1, RABGAP1, GOSR1, ZDHHC23, HSD17B4, ZDHHC24, DERL2, RRBP1, NLRC4, TRAK1, RGPD1, NAPG, STX11, ARNTL, RAB21, AP3M1, RAB20, GGA3, SNX25, LMNA, HEATR3, STX5, CCL19, BID, RAE1, RPL19, PEX16, PEX19, SYVN1, RPL23A, RAB11A, ARCN1, CENPF, SNX19, SNX17, SNX14, VPS41, RAB18, RAB3GAP2, APBA3, SEC24C]
GO:0036092;phosphatidylinositol-3-phosphate biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;663.4179201744114;5.8650506222523235;0.02220400075087234;0.6961795867550195;[SYNJ1, PIK3C3]
GO:0042771;intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;8.0;1.0;0.875;9.628524252492122;164.97679920792456;6.409777797693995;0.005521625000009403;0.7027963346592216;[CDKN1A, BCL3, DDIT4, EP300]
GO:0051492;regulation of stress fiber assembly;10.0;0.8933024483968273;0.861892236059334;9.4949928598676;106.75891518059157;5.459585514144159;0.0035731248143085707;0.6944444689509434;[SFRP1, ROCK2, PPFIA1, EPHA1, CLASP1, ARHGEF5]
GO:0043620;regulation of DNA-templated transcription in response to stress;10.0;0.6302958089695718;0.7303889163457062;8.89455507741192;277.5670074981562;5.407625775213448;0.009289917946874546;0.6917872454856517;[CREBBP, BAG3, EP300, ARNT, HIF1AN, SIRT2, RELA]
GO:0006683;galactosylceramide catabolic process;10.0;1.0;0.9152410118609203;9.628524252492122;2043.7855819387476;9.777073627680469;0.0684036641398828;0.9152410118609203;[GALC]
GO:0006446;regulation of translational initiation;8.0;0.622025257344104;0.686012628672052;8.744321835169467;215.8173094633638;5.433268205826786;0.007223211124770292;0.6528575887187926;[EIF5B, RXRA, KLHL25, YTHDF3, CCL5, TPR, EIF2AK3, POLR2G, EIF4G2]
GO:0042532;negative regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1231.6194323740242;7.379178354882098;0.041221194016031935;0.8098004765652196;[PPP2CA]
GO:1990001;inhibition of cysteine-type endopeptidase activity involved in apoptotic process;13.0;1.0;0.9625549647676366;9.628524252492122;2010.8653136723324;7.292166977892469;0.06730185238732382;0.8354767231375014;[NLRC4, UBE2Z]
GO:0031638;zymogen activation;7.0;0.8259837884571596;0.7639112594857803;9.387362195675234;102.5832240862455;6.113511981550823;0.00343336819125881;0.663564652301091;[FGA, FGG, CTSH]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[MTPN, CSNK2A1, SPHK1, H3F3A, DERL2, CIB1, RAB11A, SFRP1, RUFY3, ADNP, TRIM32, EIF4G2, PAFAH1B1, HBEGF]
GO:0010813;neuropeptide catabolic process;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;142.40199253781023;9.083926447120524;0.004766066536767652;0.8154717862087246;[CTSH]
GO:0051000;positive regulation of nitric-oxide synthase activity;7.0;1.0;0.8509193652572005;9.628524252492122;123.23454311126406;6.832634648514029;0.0041245492540456985;0.7003406189322132;[KRAS]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[SEMA6B, PPP2CA, FLCN, SERTAD3, SFRP1, CDKN1A, GAL, NPPA]
GO:0010815;bradykinin catabolic process;7.0;1.0;0.8509193652572005;9.628524252492122;198.73492378151718;8.16763571524637;0.00665147904914789;0.7686126355688037;[XPNPEP1, CTSH]
GO:0019885;antigen processing and presentation of endogenous peptide antigen via MHC class I;5.0;0.8436909121759173;0.712086467948879;9.271849308553389;32.556158890958;7.8311634786251565;0.0010896253394395913;0.6907270763441554;[TAPBP]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[DCTN5, FCER1G, DCTN4, CLTA, KLC1, DYNLL2, HLA-DMA, HLA-DMB, AP1G1, HLA-DPB1, CTSE, HLA-DRB3, SEC24C, HLA-DQA1, HLA-DPA1]
GO:2001168;positive regulation of histone H2B ubiquitination;12.0;0.9326813400603323;0.9144609826203107;9.60254876608886;1491.568393434329;8.390779266560578;0.04992145180384398;0.8772251544931927;[CDK9, RNF20]
GO:1902042;negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;425.73912115989816;6.193554689224359;0.014249105244888325;0.731979686697602;[FGA, FGG, RIPK1, TNFRSF10A, RFFL]
GO:1903373;positive regulation of endoplasmic reticulum tubular network organization;7.0;1.0;0.8509193652572005;9.628524252492122;89.85852950099016;8.390779266560578;0.0030074841149719477;0.7800242071602487;[RAB3GAP2, RAB3GAP1]
GO:0045815;positive regulation of gene expression, epigenetic;7.0;0.7763722522362496;0.7391054913753253;9.081980546124052;79.85422672196849;5.8650506222523235;0.0026726491042460506;0.6508583268319309;[TBP, WBP2, ATAD2, TAF1A, EP300, POLR1E, DEK, ARID1A]
GO:0046907;intracellular transport;4.0;0.4588307462772947;0.47941537313864735;6.383331119306548;29.648951319524702;2.4598612193206306;9.923237183406674E-4;0.3757974171513022;[RAB3B, AHCYL1, SYS1, RPL3, NCF1, CASC3, FNBP1L, IPO4, RAB43, ALKBH5, IPO8, TFG, LAMP2, ARFIP1, TBC1D22A, PLEKHJ1, VPS18, GSTK1, RPS9, COG3, COG1, THOC2, SYTL3, SRRM1, BCR, SNRPG, CHMP4B, KPNB1, ACOT4, COPB2, TMEM87A, COPA, SEH1L, CLEC16A, ATP5I, KLHL12, VPS26B, ATP5O, ATP5L, TGOLN2, FXR1, ARHGAP21, SPAST, RHOT1, TPR, VPS11, CYC1, RAB6A, VPS16, TRAPPC2, BBS2, TRAPPC3, TOR1A, CPSF2, RAB3IP, IFT122, NUP153, RAB27B, TIMM44, NFKBIA, PAN3, SYNJ1, GOLGB1, BCL3, ARF3, TRAM1, SMG1, CLTA, LYST, SMG5, TRIM9, TUBA1C, AKAP13, CPT2, AP1G1, NUP62, TMED2, TMED1, EVI5L, TNPO1, TNPO2, SPG11, RAB8B, UPF2, BCAS4, UPF1, ACTR2, GRIPAP1, TMED9, DTX3L, SSR2, TBC1D8, DYNLL2, SPTB, AFTPH, ALS2, ACOX2, TRAPPC6B, AGPS, PIK3C3, CHMP6, SLU7, PAFAH1B1, DCTN5, BECN1, RABGAP1, DCTN4, GOSR1, ZDHHC23, HSD17B4, ZDHHC24, DERL2, COX5B, TRAK1, RGPD1, NAPG, STX11, ARNTL, RAB21, AP3M1, NXF3, RAB20, GGA3, PABPN1, U2AF2, LMNA, HEATR3, STX5, NUP43, SLC25A20, BID, RAE1, RPL19, PEX16, PEX19, SYVN1, RPL23A, RAB11A, ARCN1, SNX17, VPS41, RAB18, RAB3GAP2, CAMK1, SEC24C, CLUAP1]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[COLEC12, PKD2L1, NLRC4, CLYBL, GLS, SPAST, RXRA, RNF213, RIPK1, ECT2, BID, VASP, PDCD6IP, KCND1, FCER1G, TOR1A, ATPIF1, EIF2AK3, KCTD5, MARCKS, ALDH5A1, KCTD10, IMPDH2, KCTD14, CHMP4B, ALDOA]
GO:0008631;intrinsic apoptotic signaling pathway in response to oxidative stress;7.0;0.8653626801206646;0.7836007053175329;9.523163736834295;52.930841574252625;6.943860283624253;0.001771547632825523;0.7060287030842711;[DIABLO, ARL6IP5, ZNF622]
GO:0006337;nucleosome disassembly;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;96.25424468242052;6.832634648514029;0.0032215429463244545;0.6725415662651573;[SMARCD2, HIST3H2A, ARID1A]
GO:0032715;negative regulation of interleukin-6 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;64.96654663153603;6.166155715036245;0.002174371849661483;0.6384578026126634;[NLRP12, NCKAP1L, CSK]
GO:0006449;regulation of translational termination;8.0;0.8653626801206646;0.8076813400603323;9.4949928598676;233.78685173077864;7.697632086000634;0.00782463553292257;0.7686572628545723;[UPF1, ETF1]
GO:0010824;regulation of centrosome duplication;9.0;0.7866048967936545;0.7895430735771163;9.474373572664863;54.56804827344474;6.063501560976162;0.0018263434676571142;0.706328376990269;[PDCD6IP, ROCK2, NUP62, CCNF, CHMP4B]
GO:0016482;cytosolic transport;5.0;0.7090535922965819;0.6447678080092112;8.529911963824013;33.20429938101479;4.857092701852345;0.0011113180183532213;0.5386329585115588;[TGOLN2, BECN1, TMEM87A, ACTR2, SYS1, AP1G1, GOSR1, STX5, PIK3C3, VPS26B, RAB6A, PLEKHJ1]
GO:0010825;positive regulation of centrosome duplication;10.0;0.8933024483968273;0.861892236059334;9.582004236857228;269.74818055260414;7.9853141584524145;0.009028228845494321;0.8236103492792612;[ROCK2, NUP62]
GO:0016485;protein processing;6.0;0.6519675769143192;0.6491041010473041;8.320191432841943;99.81063536400724;4.720827822332161;0.0033405721418933456;0.564543666965156;[FGA, RHBDF2, FGG, CASP2, CTSH, PIK3C3, CTSE, SEC11A]
GO:0010942;positive regulation of cell death;5.0;0.5391707831400974;0.559826403430969;7.325939159498076;41.77857356132841;3.304727333179569;0.0013982912588225433;0.45924492136526085;[HRK, CDKN1A, ITGB2, UBE2Z, ELK1, BBC3, FLCN, AKAP13, RPS6KA2, C1QBP, ARL6IP5, CASP2, CTSH, RBM5, DFFA, SAP30BP, FBXO18, ATPIF1, PLAUR, YWHAZ, SIRT2, VAV1, SFRP1, GAL, ACOX2, TFDP2, PTRH2, DDIT4, ARHGEF5, ITGB3BP, PPID, DIABLO, NLRC4, THBS1, STK3, ABR, CCL5, UBD, TP53INP1, TP53BP2, NLRP3, RIPK1, SUDS3, ZNF622, ECT2, BID, NTSR1, TFAP2A, EIF2AK3, G0S2, TNFRSF10A, HSPE1, NLRP12, IL6, FAP, MNDA, PDCD1, SERINC3]
GO:0048096;chromatin-mediated maintenance of transcription;11.0;1.0;0.9324289523296623;9.628524252492122;1311.6223032101445;7.57984905034425;0.043898818105007634;0.8200627852632958;[ARID1A]
GO:0051259;protein complex oligomerization;5.0;0.7763722522362496;0.6784271379790451;9.089527751759436;40.42272244673708;3.6012063575747084;0.0013529121422039536;0.47440687246051283;[COLEC12, PKD2L1, NLRC4, IKZF1, HSD17B8, CLYBL, GLS, SPAST, RXRA, RNF213, CCL5, NUP62, NLRP3, RIPK1, ECT2, BID, VASP, RRM1, PDCD6IP, CPSF6, KCND1, FCER1G, TOR1A, ATPIF1, EIF2AK3, PRKAB1, KCTD5, MARCKS, ALDH5A1, COL1A2, KCTD10, IMPDH2, KCTD14, CHMP4B, ALDOA]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[MAP3K3, PDE6H, THBS1, ERN1, AKAP13, KARS, DVL3, RIPK1, CSK, KRAS, CCL19, ARHGEF5, EZH2]
GO:0045948;positive regulation of translational initiation;9.0;0.7586651285174919;0.775573189439035;9.39368466141472;1253.3709905068713;6.409777797693995;0.04194919909160693;0.7240369598395108;[RXRA, YTHDF3, CCL5, POLR2G]
GO:0043408;regulation of MAPK cascade;9.0;0.6039883530135606;0.6982348016870694;8.647694999480395;157.04088149872794;3.1840290935380327;0.005256016976144841;0.5590720210963193;[ERRFI1, HDAC3, NCF1, CIB1, THBS1, DUSP14, STK3, RAP1B, PPP2CA, FLCN, AKAP13, RRAS, PRDX1, CCL5, NUP62, STK38, ARL6IP5, DVL3, RIPK1, CSK, ZNF622, CCL19, DACT1, TBX1, MAP3K3, FGA, KSR1, PDE6H, AMBP, CCL20, FGG, VRK2, ERN1, ITCH, CD4, NLRP12, SFRP1, IL6, COPS5, KARS, KRAS, EPHA1, ARHGEF5, PAFAH1B1, EZH2]
GO:1903140;regulation of establishment of endothelial barrier;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;90.35426377509846;7.292166977892469;0.003024075894994471;0.747921758369865;[ROCK2]
GO:0006783;heme biosynthetic process;7.0;0.8259837884571596;0.7639112594857803;9.464221201200845;646.2085211808783;6.781341354126479;0.02162801765401235;0.6977174774718518;[ATPIF1, CPOX, NFE2L1]
GO:0014040;positive regulation of Schwann cell differentiation;10.0;1.0;0.9152410118609203;9.628524252492122;471.693664190925;9.083926447120524;0.01578716244373315;0.8797934328124444;[RELA]
GO:0002062;chondrocyte differentiation;4.0;0.8933024483968273;0.6966512241984136;9.446202695698167;21.066225782797595;6.039404009397101;7.050676185779127E-4;0.5588554019015759;[SNX19, NFIB, RUNX2]
GO:0045820;negative regulation of glycolytic process;12.0;0.8933024483968273;0.8947715367885583;9.593432932680852;4965.344842205602;7.292166977892469;0.1661856233483844;0.8210420709600095;[DDIT4]
GO:0051151;negative regulation of smooth muscle cell differentiation;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;145.64858387880895;7.069023426578259;0.004874727027208368;0.7124295520356204;[ANKRD17, MED28]
GO:0002184;cytoplasmic translational termination;7.0;1.0;0.8509193652572005;9.628524252492122;40.68669918132259;8.67846133901236;0.0013617472059468932;0.7947362817240173;[ETF1]
GO:1905206;positive regulation of hydrogen peroxide-induced cell death;9.0;0.8933024483968273;0.8428918493787028;9.589303539338841;499.2041668992919;8.16763571524637;0.016707914211537167;0.8139338954918922;[RIPK1]
GO:0022900;electron transport chain;4.0;0.7140352122741334;0.6070176061370667;8.475844742553736;29.758801740447502;4.623782033182691;9.96000313069993E-4;0.48646042820481683;[NDUFA7, NDUFB7, NDUFB10, NCF1, TXNRD1, COX4I1, NDUFA10, ETFB, COX5B, COX6A1, COX7A2L, ALDH5A1, NDUFS7, UQCRQ, NDUFS6, IDH3B, DEGS1, CYC1, BID]
GO:0006661;phosphatidylinositol biosynthetic process;8.0;0.7508913569872202;0.7504456784936101;9.237657943805111;661.808482261977;4.917261223318797;0.022150134312343243;0.6264689676365554;[RUFY1, ARF3, VAC14, DPM3, SYNJ1, PLEKHA2, PIK3C3]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[CIITA, ONECUT2, ELL, MAML1, GFI1, ARID4A, RORA, DDX41, HOXC13, IKZF1, AATF, IKZF2, ELK1, YY1, FLCN, NIPBL, DPF2, EP300, SOX8, IER5, ZNF564, IER2, ZNF485, KLF13, PEG3, NCOA6, ARNT, FLT3LG, SENP2, SAFB, TMEM173, PPRC1, MED6, RUNX2, SIRT2, CREB3, GAL, TFDP2, IL23A, TBL1XR1, ELF4, RFX4, MTF2, TFEC, HOXB4, HDAC3, ZNF350, HDAC1, WBP2, MAX, RLF, SUPT6H, RELA, ARNTL, RXRA, RAD21, HLTF, SCAP, NLRP3, RIPK1, E2F7, E2F8, TBX1, TFAP2A, ZNF462, DR1, CREBBP, NFYC, ATAD2, PBX3, ERLIN2, ARID3B, GRHL1, USF2, FLI1, NFKB1, SETX, CDK9, NFKBIA, IL6, TFCP2, COPS5, SP1, NFIB, TNIP2, NFIC, PSMC1, SP3, MAFF, BCL3, TAF7, CAMK1, NFE2L1]
GO:0006303;double-strand break repair via nonhomologous end joining;9.0;0.8933024483968273;0.8428918493787028;9.548481544818586;368.8093148901945;5.8067817141283475;0.012343715862540626;0.693199712083778;[DCLRE1C, XRCC5]
GO:0006302;double-strand break repair;8.0;0.7586651285174919;0.754332564258746;9.318369324188282;183.0506323445446;4.689477292448085;0.006126539929698291;0.6148200868187911;[FEN1, WDR48, DCLRE1C, FBXO18, DTX3L, XRCC5, GINS4, CIB1, YY1, SETX, RAD51AP1, NIPBL, RAD51C, RAD21]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[BTG2, KRAS, ADNP, SNCB, CPEB4]
GO:1990266;neutrophil migration;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;32.18154458361247;5.277263957350204;0.0010770873357037246;0.6448795241967606;[FCER1G, WDR1, CCL20, CCL5, ITGB2, NCKAP1L, CCL19, VAV1]
GO:0010917;negative regulation of mitochondrial membrane potential;5.0;1.0;0.7902410118609202;9.628524252492122;24.658349685322438;7.697632086000634;8.252927728937918E-4;0.6838982747154925;[ARL6IP5]
GO:0051146;striated muscle cell differentiation;5.0;0.7436939687323844;0.6620879962271125;8.781226392104918;21.75937296335754;5.825829909099042;7.282666309192915E-4;0.5881742243410422;[MTPN, AKAP13, RXRA, IGFBP5, KRAS, ARID1A]
GO:0051385;response to mineralocorticoid;7.0;0.7980440201809971;0.7499413753476991;9.36615998802463;62.73690238121479;6.280566066213989;0.00209974766315278;0.6721078059595746;[CDKN1A, KRAS]
GO:0051384;response to glucocorticoid;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;62.73690238121479;4.800339885259895;0.00209974766315278;0.5964089702280253;[ERRFI1, CDKN1A, IL6, ABCC2, ABCA3, CAD, DDIT4, SDC1, KRAS, UBE2L3]
GO:0030521;androgen receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.446202695698167;54.01143535742291;5.948432231191374;0.0018077141342769656;0.6792031009335148;[ARID1A]
GO:0030520;intracellular estrogen receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;54.01143535742291;6.7325511899570465;0.0018077141342769656;0.719302980950052;[NCOA6, TAF7, SAFB, ARID1A]
GO:0016236;macroautophagy;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;39.83166466328102;5.244474134527214;0.0013331299701091492;0.5584436629936305;[BECN1, GABARAPL1, CALCOCO2, UBQLN1, C6orf106, CHMP4B, PIK3C3, CHMP6, DYNLL2, PRKAB1]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[BECN1, USP36, WDR48, USP32, USP12, OTUD7B, NEDD8, USP39, PSMB10, PSMA7, YY1, PSMD8, POLB, VCPIP1, RHOT1, PSMD7, PSMD4, PSMD2, PSMB1, NLRP3, USP51, RIPK1, SKP2, USP46, RAD23A, JOSD1, NFKBIA, COPS5, PSMA1, TNIP2, PSMC1, PSME2, USP41]
GO:1903033;positive regulation of microtubule plus-end binding;7.0;1.0;0.8509193652572005;9.628524252492122;62.700582840918095;9.083926447120524;0.002098532080824514;0.8154717862087246;[MAPRE1]
GO:1902188;positive regulation of viral release from host cell;8.0;0.9326813400603323;0.8413406700301662;9.55953138100517;120.05257821018927;7.069023426578259;0.004018051752389216;0.7365101867784198;[DDB1, CHMP4B]
GO:0006310;DNA recombination;7.0;0.612588685250814;0.6572137078826075;8.529911963824013;149.0421272461911;4.488806596985934;0.0049883058697239;0.5804771433779154;[FEN1, WDR48, DCLRE1C, FBXO18, NCOA6, XRCC5, GINS4, WRNIP1, YY1, SETX, POLB, RAD51AP1, NIPBL, RAD51C, MSH3, RAD21]
GO:0006431;methionyl-tRNA aminoacylation;11.0;0.9326813400603323;0.8987696223598284;9.590783924509275;205.4345073903719;9.083926447120524;0.006875708083302461;0.8969813732811862;[MARS]
GO:0006672;ceramide metabolic process;7.0;0.7140352122741334;0.7079369713942671;9.176539128749065;101.21355503378848;5.420364800990877;0.0033875266006951925;0.628117073252615;[PPP2CA, GALC, UGT8, SGPL1, ALDH5A1, DEGS1]
GO:0045954;positive regulation of natural killer cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.526741558182179;431.31665099041965;6.444869117505266;0.014435780148864921;0.7258315315665724;[AP1G1, VAV1]
GO:0007517;muscle organ development;4.0;0.7763722522362496;0.6381861261181248;8.753055515138222;27.682183388997124;5.085725745451326;9.264977656821302E-4;0.5100842511328143;[TBX1, FXR1, CENPF, VAMP5, HBEGF]
GO:0010923;negative regulation of phosphatase activity;9.0;0.7866048967936545;0.7895430735771163;9.362821086759116;265.75489588375854;5.142344639450834;0.008894577201350937;0.659220369185286;[ELL, PPP1R11, ROCK2, CD2BP2, PHACTR2, NCKAP1L]
GO:0010801;negative regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;780.3281191277907;7.069023426578259;0.026116879897493853;0.7767511986393403;[DDIT4, CALM1, CALM2, SIRT2]
GO:0031848;protection from non-homologous end joining at telomere;9.0;1.0;0.896240625180289;9.628524252492122;217.09097804873235;7.8311634786251565;0.007265839666095271;0.7967266896635242;[DCLRE1C, TFIP11]
GO:0010803;regulation of tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;58.00234281560482;5.734022359845919;0.001941286215318787;0.64415753539903;[HIST1H2BJ, SPHK1, RIPK1, RFFL, TRIM32]
GO:0016344;meiotic chromosome movement towards spindle pole;7.0;0.8436909121759173;0.7727648213451592;9.417215158824915;101.26836528401668;8.67846133901236;0.0033893610504443076;0.7947362817240173;[ACTR2]
GO:0061014;positive regulation of mRNA catabolic process;9.0;0.7586651285174919;0.775573189439035;9.398000593880289;689.1938106655065;6.063501560976162;0.023066696608813914;0.706328376990269;[UPF1, BTG2, YTHDF3, CNOT1, POLR2G, ZC3HAV1, CNOT8]
GO:0003091;renal water homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;57.14336741787613;6.311337724880743;0.0019125370817844765;0.6736814700148209;[RAB11A]
GO:0006486;protein glycosylation;7.0;0.6181399273706679;0.6599893289425345;8.590536585640447;174.0766208890209;4.3090134865453384;0.005826187842367879;0.5712825153487487;[GALNT12, DPM3, COG3, FUT11, SYVN1, DOLK, MAN1B1, TRAK1, GALNT10, FUT4]
GO:1901026;ripoptosome assembly involved in necroptotic process;6.0;1.0;0.8231203125901445;9.628524252492122;41.11586962729703;9.083926447120524;0.0013761111545453324;0.7876727335416686;[RIPK1]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[ONECUT2, ELL, INTS10, ARID4A, HOXC13, ELK1, AFF4, TRIM24, ZNF768, EP300, IER2, GTF2I, TBP, KLF13, ARNT, CREB3, TFDP2, ELF4, RFX4, TFEC, LCOR, WBP2, MAX, RPAP1, SUPT6H, GTF2E2, RELA, ARNTL, POLR2B, RAD21, TAF1A, HLTF, HIVEP1, POLR2G, HIVEP2, TFAP2A, POLR2J3, NFYC, INTS3, PBX3, ARID3B, DEK, GRHL1, USF2, GTF2H4, FLI1, NFKB1, CDK9, GFI1B, TFCP2, COPS5, SP1, NFIB, NFIC, MAFF, NFE2L3, INTS4, TAF7, NFE2L1]
GO:0008542;visual learning;8.0;1.0;0.875;9.628524252492122;51.65827414420079;5.970411137910149;0.00172895594617802;0.6803271032452366;[RIC8A, KRAS]
GO:0008306;associative learning;7.0;0.8436909121759173;0.7727648213451592;9.223059144383958;22.449675191779697;5.459585514144159;7.513704252729093E-4;0.6301228223472235;[RIC8A, ACTR2, BTG2, KRAS]
GO:0006368;transcription elongation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;5.459585514144159;0.015969835568764485;0.675444082270312;[CDK9, ELL, POLR2B, POLR2G, SUPT6H, GTF2H4, AFF4]
GO:0072385;minus-end-directed organelle transport along microtubule;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;91.0022540166244;8.390779266560578;0.003045763545224989;0.8041048419030481;[RAB6A]
GO:0032526;response to retinoic acid;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;43.78950961223322;5.123113277522946;0.0014655954787213788;0.5522372631225753;[SETX, TBX1, RXRA, SYNJ1, CTSH]
GO:0048169;regulation of long-term neuronal synaptic plasticity;9.0;0.8933024483968273;0.8428918493787028;9.461470167828956;42.75619717690252;6.481236761676141;0.0014310114414316764;0.7276913745807394;[KRAS, RAB11A]
GO:0033619;membrane protein proteolysis;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;49.64990487012002;6.166155715036245;0.001661737633989536;0.6384578026126634;[CTSH, PARL, NFKB1, RELA]
GO:0030220;platelet formation;5.0;1.0;0.7902410118609202;9.628524252492122;33.79744107268718;6.832634648514029;0.0011311699369806302;0.639662265535933;[WDR1, EP300, CIB1]
GO:0010611;regulation of cardiac muscle hypertrophy;7.0;0.7866048967936545;0.7442218136540277;9.260799472366804;47.00709773552042;5.926926025970411;0.0015732852575664914;0.6540226378555745;[CDK9, BECN1, MTPN, ERRFI1, AKAP13, LMNA]
GO:0016055;Wnt signaling pathway;7.0;0.5916390046238794;0.6467388675691402;7.647522783625538;28.581916314885376;4.0633408221711;9.566110170045473E-4;0.558718803867703;[TLE4, CSNK2A1, UBE2B, KLHL12, SENP2, APCDD1, DDB1, SFRP1, GNG2, GNAT2, DVL3, SDC1, TAX1BP3, CALM1, MARK2, DACT1]
GO:0032760;positive regulation of tumor necrosis factor production;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;85.9095484537234;5.587418885654044;0.002875315273172136;0.6366602269110988;[FCER1G, IL23A, RIPK1, CCL19, THBS1, CCR2]
GO:0017148;negative regulation of translation;8.0;0.6493065804076676;0.6996532902038338;9.081980546124052;1114.6737408694362;4.99795013456894;0.03730712696566269;0.6305954023103058;[UPF1, BTG2, IGFBP5, YTHDF3, EIF2AK3, CNOT10, FXR1, EIF4ENIF1, ILF3, XRN1, CNOT1, TPR, EIF4E2, CNOT8, CPEB4]
GO:0010972;negative regulation of G2/M transition of mitotic cell cycle;9.0;0.811012628672052;0.801746939516315;9.394909401310617;357.14964968422294;5.926926025970411;0.011953477361114177;0.699343897778663;[FANCI, GPR132, RAD21]
GO:0051568;histone H3-K4 methylation;11.0;0.8653626801206646;0.8651102923899945;9.53008417967887;767.5947827162904;6.250713103064308;0.02569070658705971;0.7520907111082569;[RBBP5, ARID4A, RLF]
GO:0010971;positive regulation of G2/M transition of mitotic cell cycle;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;355.9636244052406;6.481236761676141;0.011913782162380092;0.7276913745807394;[RAD51C, RAB11A]
GO:0032402;melanosome transport;8.0;1.0;0.875;9.628524252492122;154.03816563912218;6.686031174322154;0.005155518778592664;0.7169239451870815;[BBS2, RAB27B, RAB11A]
GO:0061001;regulation of dendritic spine morphogenesis;11.0;0.8933024483968273;0.8790801765280758;9.548481544818586;263.40314350006116;6.166155715036245;0.00881586616550832;0.747766442352181;[ACTR2, CFL1, LRP8, PAFAH1B1]
GO:0061003;positive regulation of dendritic spine morphogenesis;12.0;1.0;0.9481203125901445;9.628524252492122;1908.9696229991087;6.943860283624253;0.06389149532065895;0.8032296504172152;[ACTR2, LRP8, PAFAH1B1]
GO:0060271;cilium assembly;6.0;0.8653626801206646;0.7558016526504768;9.405380701177911;137.68250629835126;4.347727998726029;0.00460810957959482;0.5454633246350222;[BBS2, SPAG16, ACTR2, ONECUT2, RFX4, TMEM107, IFT122, CCDC65, FNBP1L, SNAP29, DYNLL2, CLUAP1]
GO:0006497;protein lipidation;7.0;0.6519675769143192;0.6769031537143602;8.673012807464685;151.15475272427284;5.382624473008031;0.005059013543235805;0.6261870311244675;[DPM3, ZDHHC23, ZDHHC5, ZDHHC24, PIK3C3]
GO:0038061;NIK/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.8867018697843045;8.845336528452411E-4;0.6753065664753021;[NFKB1, RELA]
GO:1902004;positive regulation of amyloid-beta formation;8.0;1.0;0.875;9.628524252492122;442.71613466832366;7.474488534686424;0.01481731060869512;0.7572456912631272;[ROCK2]
GO:1990182;exosomal secretion;7.0;1.0;0.8509193652572005;9.628524252492122;38.46917486033492;8.390779266560578;0.0012875286625657566;0.7800242071602487;[COPS5, RAB11A]
GO:0030217;T cell differentiation;6.0;0.657518819034173;0.651879722107231;8.679443697794976;65.04859315339479;5.132682728539097;0.00217711787291102;0.5856059460217904;[CD4, FCER1G, SP3, BCL3, RORA, ATP7A, RUNX2, VAV1]
GO:0032757;positive regulation of interleukin-8 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;5.948432231191374;0.002183412136085803;0.6273234135236593;[RIPK1, CD244]
GO:0032515;negative regulation of phosphoprotein phosphatase activity;10.0;0.8653626801206646;0.8479223519212526;9.5525383455142;1090.4524045737035;5.788089581116195;0.03649646063763195;0.7112441822128948;[PPP1R11, ROCK2, PHACTR2, NCKAP1L]
GO:0030218;erythrocyte differentiation;5.0;0.8436909121759173;0.712086467948879;9.117698628726131;22.675663695230284;5.885253329569843;7.589340571069517E-4;0.5912131408273906;[SP3, ATPIF1, IKZF1, NFE2L1]
GO:0097211;cellular response to gonadotropin-releasing hormone;8.0;1.0;0.875;9.628524252492122;462.69925393661634;7.8311634786251565;0.015486127626965131;0.7754860644832351;[RAP1B]
GO:0010989;negative regulation of low-density lipoprotein particle clearance;6.0;1.0;0.8231203125901445;9.628524252492122;57.61250424992052;8.16763571524637;0.0019282386693572648;0.7408135829017477;[CSK]
GO:0071168;protein localization to chromatin;7.0;0.7369933605727446;0.7194160455435727;8.935377071932177;34.71951895434896;6.832634648514029;0.001162031053863633;0.7003406189322132;[NIPBL, RAD21, EZH2]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[NCF1, MAML1, GFI1, CD80, ARID4A, RORA, IKZF1, IKZF2, ELK1, YY1, ZXDC, DPF2, TRIM24, EP300, SOX8, IER5, ZNF564, IER2, RPS9, FLT3LG, PRKAB1, MED6, RUNX2, ERN1, OLFM1, ILF3, SFRP1, KARS, IL23A, TBL1XR1, RFX4, HOXB4, MAX, RLF, SUPT6H, C3, FXR1, RAD21, HLTF, DVL3, SCAP, NLRP3, RIPK1, TFAP2A, DR1, CREBBP, PBX3, EIF2AK3, ERLIN2, FLI1, NFKB1, SETX, CDK9, NFKBIA, IL6, TFCP2, COPS5, SP1, SP3, MAFF, BCL3, NFE2L3, NFE2L1, CDKN1C, CIITA, ONECUT2, ELL, DDX41, HOXC13, AATF, FLCN, NIPBL, LBH, C1QBP, NUP62, TMED2, CTSH, ZNF485, TBP, KLF13, PEG3, DTX3L, NCOA6, ITGA2, ARNT, SENP2, SAFB, TMEM173, PPRC1, ARID1A, SIRT2, CREB3, GAL, TFDP2, ELF4, MTF2, TFEC, POLR1E, HDAC3, ZNF350, HDAC1, WBP2, ROCK2, THBS1, RELA, ARNTL, SERTAD3, RXRA, U2AF2, TP53INP2, CCL5, TP53INP1, LMNA, TAF1A, POLR2G, GPBP1L1, E2F7, E2F8, TBX1, RNF20, ZNF462, CHURC1, YTHDF3, NFYC, ATAD2, ARID3B, DEK, GRHL1, USF2, CD4, NFIB, TNIP2, NFIC, CAMK4, MARS, PSMC1, TAF7, KRAS, CAMK1, RAB3GAP1, LIMS1]
GO:0010507;negative regulation of autophagy;7.0;0.7436939687323844;0.7227663496233927;9.117698628726131;217.48068666745357;5.500407508664414;0.007278882862848883;0.6322104610454062;[BECN1, USP36, HERC1, CLEC16A, CHMP4B, SIRT2, RASIP1, EIF4G2]
GO:0016042;lipid catabolic process;4.0;0.5127202928476964;0.5063601464238482;6.883086519318291;43.14795622097559;4.114113147544524;0.0014441232640765526;0.4603959376912539;[HSD3B7, PLA2G12A, SPHK1, HSD17B4, ETFB, SIRT2, GALC, SGPL1, ACOX2, CPT2, SNX17, TBL1XR1, DAGLB, HRASLS, SCARF1, MGLL, PAFAH1B1]
GO:0070198;protein localization to chromosome, telomeric region;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;34.71951895434896;7.138016298065211;0.001162031053863633;0.7159578506919597;[XRCC5]
GO:0001913;T cell mediated cytotoxicity;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;37.17052405245288;7.292166977892469;0.001244063988735793;0.6960420709600095;[CTSH]
GO:0018345;protein palmitoylation;8.0;0.811012628672052;0.780506314336026;9.370695143190021;306.991636675669;6.311337724880743;0.010274733804998895;0.6977621047576203;[ZDHHC23, ZDHHC5, ZDHHC24]
GO:0001916;positive regulation of T cell mediated cytotoxicity;9.0;0.8653626801206646;0.8289219652406215;9.523163736834295;365.14378084230765;6.518977089658987;0.012221033736724321;0.7296214167088868;[IL23A, HLA-A, HLA-F]
GO:0010744;positive regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;113.85781812010546;7.004484905440688;0.0038107187070962377;0.6813299963962409;[NFKB1]
GO:0018105;peptidyl-serine phosphorylation;9.0;0.7369933605727446;0.7647373054666613;9.207310787415818;338.73676479787366;4.61801832846594;0.011337214674488616;0.6324062972578516;[SMG1, MAST3, ROCK2, EIF2AK3, VRK2, CLK1, ERN1, CAMK4, STK38, MKNK2, STK38L, RIPK1, CAMK1, MARK2]
GO:0048172;regulation of short-term neuronal synaptic plasticity;9.0;0.8933024483968273;0.8428918493787028;9.461470167828956;42.75619717690252;7.069023426578259;0.0014310114414316764;0.757750811958709;[RAB3GAP1]
GO:0032874;positive regulation of stress-activated MAPK cascade;11.0;0.7980440201809971;0.8314509624201607;9.52534001625689;1523.641600475785;4.753193106834193;0.05099491317950919;0.6755074688592472;[ERN1, MAP3K3, KARS, NCF1, ARL6IP5, DVL3, RIPK1, ZNF622, CCL19, ARHGEF5, STK3]
GO:0032753;positive regulation of interleukin-4 production;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;64.94897299966192;6.686031174322154;0.0021737836760178982;0.665044257777226;[NLRP3]
GO:0018107;peptidyl-threonine phosphorylation;9.0;0.7671156992804218;0.7797984748205;9.305750860229072;337.99482745314367;5.395046993006588;0.011312382699260763;0.6721435792979885;[CLK1, CSNK2A1, ROCK2, CAD, CAMK1, OXSR1, MARK2]
GO:0030336;negative regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.20713857156096;158.04059951544355;4.3090134865453384;0.00528947663847651;0.5712825153487487;[RNF20, STARD13, MCTP1, IGFBP5, IDH2, THBS1, BCR, ABR, FLCN, SFRP1, RRAS, TBXA2R, ADORA3, TP53INP1, ARHGDIB, EPHA1, CLASP1]
GO:0032754;positive regulation of interleukin-5 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;7.212124270218933;0.002183412136085803;0.6919486831672181;[NLRP3]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[CD151, ONECUT2, ROCK2, DOCK8, ITGB3, CIB1, THBS1, NIPBL, C1QBP, CCL5, CTSH, NCKAP1L, CCL19, ATP7A, CLASP1, CCR2, SEMA6B, MAP3K3, IGFBP5, CCL20, ITGA2, SPHK1, RAB11A, PTP4A1, VIL1, CREB3, IL6, KARS, SP1, IL23A, RUFY3, EPHA1, MAPRE1, TRIM32, HBEGF]
GO:1904430;negative regulation of t-circle formation;9.0;1.0;0.896240625180289;9.628524252492122;624.9910557059465;8.16763571524637;0.02091788817904559;0.8139338954918922;[XRCC5]
GO:0061157;mRNA destabilization;10.0;0.9326813400603323;0.8815816818910864;9.61082467539272;2713.9359790271533;6.599019797332524;0.09083299483423068;0.7527151911823093;[UPF1, YTHDF3]
GO:0006344;maintenance of chromatin silencing;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;21.24116723228514;8.390779266560578;7.10922751455178E-4;0.7193458537639684;[UBE2B, ARID1A]
GO:0051591;response to cAMP;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;79.54904468548885;5.192106149009898;0.0026624349361310785;0.5886448625081389;[RAP1B, IGFBP5, ITPR2, SDC1, RELA]
GO:1903347;negative regulation of bicellular tight junction assembly;7.0;1.0;0.8509193652572005;9.628524252492122;107.40702245958384;8.390779266560578;0.003594816381677759;0.7800242071602487;[ROCK2]
GO:0006468;protein phosphorylation;7.0;0.5708408884191841;0.6363398094667926;8.175090588534603;177.75756772840523;2.970244267288293;0.005949385820444992;0.5028177952168079;[OXTR, SMG1, MAST3, MAML1, IL5RA, STK19, AKAP13, ZMYM2, RPS6KA2, CFL1, TRIM24, CTSH, CSNK2A1, KSR1, CAD, VRK2, OXSR1, GFRA2, SPTB, PRKAB1, ERN1, BCR, ILF3, KARS, PDIK1L, FASTKD5, PIK3C3, EPHA1, HBEGF, ROCK2, RASGRP4, STK3, NUAK1, PABPN1, STK35, CCL5, STK38, MKNK2, STK38L, NCAM1, MBP, RIPK1, CSK, MARK2, MAP3K3, EIF2AK3, ERLIN2, CLK4, GTF2H4, CLK3, NFKB1, SETX, CLK1, CDK9, SNRK, PAN3, PTPRA, FES, TNIP2, CAMK4, CCM2, KRAS, CAMK1, CALM1]
GO:0009615;response to virus;5.0;0.7436939687323844;0.6620879962271125;8.801845679307654;27.267803904038782;4.174954806800768;9.126288572378991E-4;0.503748394835965;[BECN1, DDX41, ZC3HAV1, LYST, RELA, CCL5, CFL1, NLRP3, CCL19, IFNAR2, APOBEC3F, DTX3L, APOBEC3H, TMEM173, UNC13D, ITCH, ILF3, IL6, POLR3C, IL23A, BCL3, POLR3E, DDIT4, SERINC3, EXOC1]
GO:0042997;negative regulation of Golgi to plasma membrane protein transport;9.0;0.8933024483968273;0.8428918493787028;9.590783924509275;462.6485801827257;8.390779266560578;0.01548443162202583;0.8253454670833372;[CSK]
GO:0032869;cellular response to insulin stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;5.334422371190153;0.015486127626965131;0.6478026081386739;[ERRFI1, SP1, MARS, RAB8B]
GO:0051225;spindle assembly;7.0;0.7508913569872202;0.7263650437508107;9.168991923113682;86.84099814437;5.266214121163619;0.00290649005606778;0.6202338003175094;[HDAC3, TUBGCP2, FBXO5, MAPRE1, KPNB1, CLASP1, RAB11A]
GO:0032868;response to insulin;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;4.800339885259895;0.0024778305216419678;0.5964089702280253;[ERRFI1, GAL, SP1, MAX, MARS, NPPA, CAD, SCAP, RELA, RAB8B]
GO:0010719;negative regulation of epithelial to mesenchymal transition;6.0;0.8259837884571596;0.7361122068187242;9.434368238051164;171.1659509920613;6.481236761676141;0.005728770340349481;0.6545710619905948;[PPP2CA, SFRP1]
GO:0051223;regulation of protein transport;6.0;0.4893904887588214;0.5678155569695552;7.04452670005989;29.137401005525486;3.3124853239905083;9.752025896965068E-4;0.49252096610533996;[USP36, CDKN1A, PPP1R11, ITGB2, CIB1, UBE2L3, NPEPPS, NUP62, ARFIP1, FGA, IL4R, ATPIF1, RHBDF2, FGG, THOC2, TMEM173, SFRP1, KARS, RUFY3, PIK3C3, LCP1, ARHGEF5, PPID, EXOC1, HDAC3, ITPR2, DERL2, SUPT6H, PARL, TM9SF4, ARNTL, NLRP7, BAG3, CCL5, TPR, VPS11, NLRP3, MBP, CSK, CCL19, ECT2, TMEM30A, EDEM1, IDH2, GLMN, RAB11A, PER2, NLRP12, IL6, PKIA, CAMK1, CD244]
GO:0010956;negative regulation of calcidiol 1-monooxygenase activity;10.0;1.0;0.9152410118609203;9.628524252492122;1348.0729573390952;8.67846133901236;0.045118788695244674;0.8590579283277371;[GFI1, NFKB1]
GO:0051584;regulation of dopamine uptake involved in synaptic transmission;8.0;0.8653626801206646;0.8076813400603323;9.537552474286395;124.06405649745743;7.697632086000634;0.0041523123205680105;0.7686572628545723;[RAB3B, TOR1A]
GO:0032508;DNA duplex unwinding;7.0;0.7980440201809971;0.7499413753476991;9.223059144383958;23.726073882073138;5.734022359845919;7.940903407527885E-4;0.64415753539903;[SETX, FBXO18, XRCC5, GINS4, ASCC3, CHD1, GTF2H4, MCM2]
GO:0010951;negative regulation of endopeptidase activity;10.0;0.7671156992804218;0.7987988615011312;9.446202695698167;500.3238742612354;4.2676852910524925;0.016745389809270216;0.6334906361130068;[SERPINA3, CSTB, SERPINB1, CSTA, ITIH2, CSNK2A1, AMBP, SERPINA10, PLAUR, TNFRSF10A, NLRC4, UBE2Z, THBS1, SERPINB6, VIL1, C3, NLRP7, RFFL, A2M]
GO:0032984;protein-containing complex disassembly;4.0;0.609056648853049;0.5545283244265244;7.6590836060266145;35.40858452208994;4.369901856220351;0.001185093458297174;0.4734769841483272;[SMARCD2, WDR1, MRPS36, MRPL17, KLC1, KIF19, MRPL40, LAMP2, CFL1, UBQLN1, DVL3, SNAP29, VPS16, GABARAPL1, MRPS24, MRPS22, MRPS18A, TFIP11, ARID1A, CKAP5, VIL1, HIST3H2A, SYNJ1, SNX14, DDIT4, ETF1]
GO:0060297;regulation of sarcomere organization;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;165.46881499726612;7.8311634786251565;0.005538092325693202;0.7967266896635242;[AKAP13]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[NAB1, GFI1, ARID4A, IKZF1, IKZF2, ELK1, UBE2L3, YY1, SAP130, ZXDC, DPF2, TRIM24, EP300, ZNF326, SOX8, ZNF688, IER5, ZNF564, IER2, GTF2I, TLE4, ZNF441, SAP30BP, CSNK2A1, ZNF282, SND1, ERN1, EID1, ILF3, ZNF93, EWSR1, TBL1XR1, RFX4, HOXB4, TIMELESS, ADNP, ZNF276, ZNF550, ZNF395, ZNF394, MAX, FOXG1, ZNF20, RPAP1, RLF, SUPT6H, GTF2E2, RAD21, ZNF549, HLTF, HIVEP1, ZNF548, HESX1, NLRP3, SUDS3, HIVEP2, ZNF544, TRAPPC2, TFAP2A, ZNF264, DR1, ZNF260, XRCC5, INTS3, PBX3, CNOT10, FLI1, NFKB1, SOX30, CDK9, CNOT6, IRAK1BP1, TFCP2, COPS5, CNOT1, SP1, SP3, ZNF30, MAFF, BCL3, ZNF658, NFE2L3, INTS4, CNOT8, TMEM18, ZNF532, ZNF410, NFE2L1, EZH2, PHF3, SETD5, CIITA, BTG2, ONECUT2, ELL, INTS10, ATF7IP2, HOXC13, CHD1, AFF4, NIPBL, ZMYM2, LBH, SCML1, C1QBP, ZNF407, NUP62, ZNF768, ZNF525, LRRFIP1, HIF1AN, ZNF485, TSC22D4, KLF12, TBP, KLF13, BUD31, COMMD3, ARNT, BAZ1A, SAFB, PPRC1, ARID1A, ZFX, MED29, SIRT2, MED28, CREB3, ZNF519, TFDP2, ELF4, TFEC, LCOR, VGLL4, ZNF630, ITGB3BP, SMARCD2, HDAC3, ZNF350, HDAC1, WBP2, ZNF69, RELA, ARNTL, SERTAD3, POLR2B, RBBP5, TP53INP2, FAM120B, TP53INP1, TAF1A, POLR2G, GPBP1L1, ASCC3, E2F7, ZNF189, E2F8, TBX1, POLR2J3, ZNF462, CHURC1, EYA2, NFYC, ATAD2, ARID3B, DEK, GRHL1, USF2, GTF2H4, PER2, GFI1B, POLR3C, NFIB, TNIP2, NFIC, MARS, POLR3E, TAF7, MNDA, ZNF696]
GO:1903233;regulation of calcium ion-dependent exocytosis of neurotransmitter;11.0;0.8933024483968273;0.8790801765280758;9.551563211355994;263.2112308779144;9.083926447120524;0.008809443022755213;0.8969813732811862;[RAB3GAP1]
GO:0009743;response to carbohydrate;4.0;0.6347111282356054;0.5673555641178027;8.102467948997072;27.321196622860832;4.720827822332161;9.144158634865458E-4;0.49142335437501145;[ERN1, RAP1B, ITGA2, ADNP, THBS1]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[MAML1, GFI1, IKZF1, IKZF2, ELK1, UBE2L3, TIAL1, SAP130, ZXDC, DPF2, TRIM24, SOX8, FBXO5, IER5, IER2, SAP30BP, CSNK2A1, ZNF282, FLT3LG, SND1, MED6, RUNX2, EID1, THAP6, SFRP1, TWSG1, KARS, IL23A, EWSR1, RFX4, BOLA3, HOXB4, TRIM14, ZNF276, ZNF395, ZNF394, FOXG1, ZNF20, RAD21, HLTF, HIVEP1, HESX1, SCAP, HIVEP2, ZNF264, CREBBP, ZNF260, XRCC5, H3F3A, PBX3, EIF2AK3, ERLIN2, FLI1, SOX30, SETX, GOLGB1, PKIA, ZNF30, EZH2, CDKN1C, SETD5, AHCTF1, BTG2, CDKN1A, ELL, ATF7IP2, OTUD7B, HOXC13, AATF, NIPBL, ZMYM2, SCML1, C1QBP, ZNF485, TSC22D4, NCOA6, SPHK1, COMMD3, BAZ1A, TMEM173, PPRC1, ZFX, MED29, SIRT2, VAV1, MED28, TOX4, GAL, MTF2, TFEC, VGLL4, ARHGEF5, ZNF350, NEDD8, TRAK1, ZNF69, RELA, ARNTL, PPP2CA, SERTAD3, RXRA, UBN1, GPBP1L1, SCAND1, ZNF462, NFYC, ATAD2, GRHL1, GTF2H4, PER2, ITCH, NLRP12, CENPF, GFI1B, HIST3H2A, NFIB, NFIC, CAMK4, MARS, PSMC1, CAMK1, ZNF696, LIMS1, NCF1, NAB1, CD80, GMNN, ARID4A, CIB1, RORA, YY1, ADORA3, WWC3, EP300, SNIP1, ZNF326, ZNF688, FADS1, ZNF564, GTF2I, TLE4, ZNF441, SSU72, ERN1, ILF3, ZNF93, TBL1XR1, TIMELESS, ADNP, PPID, ZNF550, MAX, RLF, SUPT6H, GTF2E2, STK3, BAG3, TPR, ZNF549, ZNF548, DVL3, NLRP3, RIPK1, SUDS3, ZNF544, TRAPPC2, TFAP2A, DR1, UBE2I, CNOT10, NFKB1, CDK9, NFKBIA, CNOT6, IRAK1BP1, IL6, TFCP2, COPS5, CNOT1, SP1, SP3, MAFF, BCL3, ZNF658, NFE2L3, CNOT8, ZNF532, ZNF410, NFE2L1, USP36, CIITA, ONECUT2, ITGB2, DDX41, CHD1, AFF4, FLCN, LBH, ZNF407, NUP62, GATAD1, ZNF768, ZNF525, LRRFIP1, HIF1AN, DACT1, KLF12, TBP, KLF13, PEG3, DTX3L, BUD31, ZFP91, ARNT, SENP2, SAFB, ARID1A, CREB3, ZNF519, TFDP2, SETBP1, ELF4, LCOR, ZNF630, ITGB3BP, MTPN, SMARCD2, HDAC3, HDAC1, WBP2, NLRC4, LRP8, RBBP5, TP53INP2, FAM120B, TP53INP1, TAF1A, ASCC3, ZNF622, E2F7, ZNF189, E2F8, IRX1, TBX1, RNF20, CHURC1, EYA2, FBXL15, ARID3B, DEK, USF2, CD4, POLR3C, TNIP2, TAF7, MNDA, KRAS, TRIM32]
GO:0007565;female pregnancy;3.0;1.0;0.6981203125901445;9.628524252492122;32.8060485501291;5.299736813202263;0.0010979889214459554;0.4691490996802742;[CLIC5, OXTR, ABCC2, AMBP, IGFBP5, SPHK2, ITGA2, CAD, LNPEP, COMT, CRHR1, BYSL, NPPA, KRAS]
GO:0006479;protein methylation;8.0;0.5860072649471136;0.6680036324735568;8.391761625343195;206.79845698774034;4.917261223318797;0.006921358248851439;0.6264689676365554;[RAB3B, BTG2, RBBP5, ARID4A, ETF1, RAB6A, RLF, PCMTD1, EZH2]
GO:0061028;establishment of endothelial barrier;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;35.449043474319204;6.641579411751319;0.0011864475830175945;0.6627709925721352;[RAP1B]
GO:0006117;acetaldehyde metabolic process;4.0;0.8933024483968273;0.6966512241984136;9.34084218004034;30.56973195666451;9.777073627680469;0.0010231414176169638;0.75;[RELA]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[MAML1, GFI1, ARID4A, RORA, IKZF1, IKZF2, ELK1, YY1, TIAL1, SAP130, ZXDC, DPF2, WWC3, EP300, SOX8, IER5, ZNF564, IER2, GTF2I, TLE4, ZNF441, ZNF282, SSU72, FLT3LG, MED6, RUNX2, EID1, THAP6, SFRP1, TWSG1, ZNF93, IL23A, TBL1XR1, RFX4, BOLA3, HOXB4, TIMELESS, ADNP, PPID, ZNF276, ZNF550, ZNF395, ZNF394, MAX, FOXG1, ZNF20, RLF, SUPT6H, BAG3, RAD21, TPR, ZNF549, HLTF, HIVEP1, ZNF548, HESX1, SCAP, NLRP3, RIPK1, SUDS3, HIVEP2, ZNF544, TFAP2A, ZNF264, DR1, CREBBP, UBE2I, ZNF260, PBX3, ERLIN2, FLI1, NFKB1, SOX30, SETX, CDK9, NFKBIA, IL6, TFCP2, COPS5, CNOT1, SP1, PKIA, SP3, ZNF30, MAFF, BCL3, ZNF658, NFE2L3, ZNF532, ZNF410, NFE2L1, EZH2, CIITA, AHCTF1, BTG2, CDKN1A, ONECUT2, ELL, OTUD7B, DDX41, HOXC13, AATF, CHD1, FLCN, NIPBL, ZMYM2, C1QBP, ZNF407, GATAD1, ZNF768, ZNF525, LRRFIP1, HIF1AN, DACT1, ZNF485, TSC22D4, KLF12, TBP, KLF13, PEG3, NCOA6, BUD31, ZFP91, ARNT, SENP2, SAFB, TMEM173, PPRC1, ARID1A, ZFX, SIRT2, TOX4, CREB3, GAL, ZNF519, TFDP2, SETBP1, ELF4, MTF2, TFEC, LCOR, SMARCD2, HDAC3, ZNF350, HDAC1, WBP2, NEDD8, TRAK1, LRP8, ZNF69, RELA, ARNTL, RXRA, UBN1, ZNF622, E2F7, ZNF189, E2F8, IRX1, TBX1, ZNF462, NFYC, ATAD2, FBXL15, ARID3B, DEK, GRHL1, USF2, GTF2H4, PER2, GFI1B, NFIB, TNIP2, NFIC, PSMC1, TAF7, CAMK1, ZNF696]
GO:0042766;nucleosome mobilization;6.0;1.0;0.8231203125901445;9.628524252492122;58.07307143809032;8.390779266560578;0.0019436534386617491;0.7522251544931926;[ARID1A]
GO:0032736;positive regulation of interleukin-13 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.23665507211369;7.069023426578259;0.002183412136085803;0.6846304993685643;[NLRP3]
GO:0098887;neurotransmitter receptor transport, endosome to postsynaptic membrane;14.0;1.0;0.9759193652572005;9.628524252492122;916.754991217747;7.9853141584524145;0.030682964530131116;0.8842887026755413;[GRIPAP1, RAB11A]
GO:0030433;ubiquitin-dependent ERAD pathway;10.0;0.9326813400603323;0.8815816818910864;9.600353375525426;603.0491029665483;5.557565922504363;0.02018351076733335;0.6994551915910392;[EDEM1, PSMC1, SYVN1, UBQLN1, DERL2, MAN1B1, ERLIN2]
GO:0006281;DNA repair;7.0;0.6281612110245125;0.6649999707694567;8.781226392104918;180.342582143442;3.582668236575797;0.006035903926554339;0.534137185486798;[USP36, FEN1, BTG2, SMG1, WDR48, DCLRE1C, CIB1, YY1, POLB, RAD51AP1, NIPBL, CHAF1A, POLR2B, RAD21, EP300, POLR2G, USP51, FANCI, UPF1, AQR, UBE2B, FBXO18, DTX3L, NCOA6, EYA2, XRCC5, INTS3, GINS4, RAD23A, GTF2H4, SETX, CDK9, DDB1, SMUG1, NEIL3, HIST3H2A, COPS5, RAD51C, MSH3, UBE2T, TIMELESS]
GO:0007131;reciprocal meiotic recombination;9.0;1.0;0.896240625180289;9.628524252492122;175.07189671554147;6.343086423195323;0.005859498828591432;0.7206263598461826;[RAD51C, MSH3, RAD21]
GO:0007250;activation of NF-kappaB-inducing kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1337.9940718610228;6.8867018697843045;0.04478145746870162;0.8003065664753022;[ZFP91, TNFRSF10A]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[OXTR, WBP2, THBS1, RELA]
GO:0044794;positive regulation by host of viral process;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;73.668224302776;7.212124270218933;0.002465609170316412;0.7197477358342742;[CFL1]
GO:0007257;activation of JUN kinase activity;14.0;1.0;0.9759193652572005;9.628524252492122;8640.54909511404;6.088194173566533;0.2891914022241413;0.7872698984233759;[ERN1, RIPK1, CCL19]
GO:0046854;phosphatidylinositol phosphorylation;8.0;1.0;0.875;9.628524252492122;218.7418113453505;5.049685808968129;0.007321091570879569;0.6332411671050352;[SMG1, CD80, PIK3C3, VAV1, HBEGF]
GO:0008344;adult locomotory behavior;3.0;0.8436909121759173;0.6199657686781032;9.158520623246385;24.575257889458463;5.459585514144159;8.225117652639858E-4;0.47732376968016754;[CSTB, PBX3, NTSR1, PAFAH1B1, ARCN1]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[MTPN, SPHK1, ITGB2, TRIM14, NLRP3, CIB1, RIPK1, KRAS, NLRC4, TRIM32, NFKB1, RELA]
GO:0000972;transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;21.24116723228514;7.697632086000634;7.10922751455178E-4;0.6838982747154925;[RAE1]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[C3, MAP3K3, RRAS, SP1, TBXA2R, SPHK1, ITGB2, CTSH, CIB1, EPHA1, THBS1]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[CDKN1C, USP36, CIITA, BTG2, NAB1, GFI1, GMNN, ARID4A, OTUD7B, IKZF1, IKZF2, YY1, FLCN, NIPBL, C1QBP, SAP130, DPF2, TRIM24, WWC3, EP300, SOX8, LRRFIP1, HIF1AN, ZNF564, DACT1, TLE4, ZNF485, TSC22D4, KLF12, PEG3, ZNF282, ARID1A, RUNX2, SIRT2, EID1, ILF3, SFRP1, ZNF93, TFDP2, TBL1XR1, MTF2, HOXB4, TIMELESS, LCOR, PPID, HDAC3, ZNF350, HDAC1, MAX, FOXG1, LRP8, SUPT6H, RELA, ARNTL, RXRA, BAG3, TPR, HIVEP1, HESX1, SUDS3, E2F7, ZNF189, E2F8, IRX1, TFAP2A, DR1, CREBBP, UBE2I, XRCC5, NFYC, H3F3A, NFKB1, PER2, CENPF, GFI1B, HIST3H2A, CNOT1, NFIB, NFIC, PKIA, SP3, BCL3, ZNF658, NFE2L3, TAF7, EZH2, LIMS1]
GO:0001942;hair follicle development;4.0;1.0;0.75;9.628524252492122;22.36266381479647;6.166155715036245;7.48458232790436E-4;0.5653374900225189;[HOXC13, APCDD1, RELA]
GO:0045651;positive regulation of macrophage differentiation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;840.7838216260375;7.212124270218933;0.0281402778535103;0.7650689957573628;[RIPK1]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[NCF1, MAML1, GFI1, CD80, ARID4A, RORA, IKZF1, IKZF2, ELK1, YY1, ZXDC, DPF2, TRIM24, EP300, SOX8, IER5, ZNF564, IER2, FLT3LG, MED6, RUNX2, ILF3, SFRP1, KARS, IL23A, TBL1XR1, RFX4, HOXB4, MAX, RLF, SUPT6H, RAD21, HLTF, DVL3, SCAP, NLRP3, RIPK1, TFAP2A, DR1, CREBBP, PBX3, EIF2AK3, ERLIN2, FLI1, NFKB1, SETX, CDK9, NFKBIA, IL6, TFCP2, COPS5, SP1, SP3, MAFF, BCL3, NFE2L3, NFE2L1, CDKN1C, CIITA, ONECUT2, ELL, DDX41, HOXC13, AATF, FLCN, NIPBL, LBH, NUP62, ZNF485, TBP, KLF13, PEG3, DTX3L, NCOA6, ARNT, SENP2, SAFB, TMEM173, PPRC1, ARID1A, SIRT2, CREB3, GAL, TFDP2, ELF4, MTF2, TFEC, HDAC3, ZNF350, HDAC1, WBP2, RELA, ARNTL, SERTAD3, RXRA, TP53INP2, TP53INP1, GPBP1L1, E2F7, E2F8, TBX1, RNF20, ZNF462, CHURC1, NFYC, ATAD2, ARID3B, GRHL1, USF2, CD4, NFIB, TNIP2, NFIC, CAMK4, MARS, PSMC1, TAF7, CAMK1]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[ELL, UBE2B, RIC8A, FLCN, RXRA, ALS2, MAFF, CCM2, SOX8, EIF4E2, ATP7A, APBA3, SEC24C]
GO:0031116;positive regulation of microtubule polymerization;10.0;0.8933024483968273;0.861892236059334;9.589303539338841;431.61701704611926;6.518977089658987;0.014445833130437288;0.7486218033895181;[FES, MAPRE1, CLASP1]
GO:0034504;protein localization to nucleus;6.0;0.7192862368539868;0.682763431017138;8.763526815005518;32.77360880529348;4.8942717050940985;0.001096903192380182;0.5734135951955668;[IPO8, TOR1A, NUP62, LMNA, HEATR3, NUP153, TNPO1, TNPO2, RGPD1, RAE1, KPNB1, IPO4]
GO:0032204;regulation of telomere maintenance;7.0;0.6519675769143192;0.6769031537143602;8.969278623607858;103.7409614847858;5.395046993006588;0.003472116620091941;0.6268223193749;[UPF1, SMG1, GNL3L, XRN1, XRCC5, SMG5, DCP2]
GO:0031115;negative regulation of microtubule polymerization;10.0;0.9326813400603323;0.8815816818910864;9.587702257971866;405.4514152206468;7.292166977892469;0.013570093984851534;0.7881627702307852;[MAPRE1, EML2]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[RPL3, NDUFA11, NCF1, NDUFA10, GMNN, PKD2L1, IKZF1, TMEM141, IPO4, GLS, PSMD8, PSMD4, TFG, EP300, OIP5, FBXO5, TLE4, PRKAB1, KCTD5, MED6, COX7A2L, KCTD10, PRPF3, SNRPG, KCTD14, CHMP4B, CD2BP2, TSPYL6, PPID, HIST1H2BC, NDUFB10, TUBGCP2, YTHDC1, EPB41, MAX, KLHL12, ATXN2, SPAST, RNF213, TSPAN4, NLRP3, NCKAP1L, RIPK1, ECT2, TRAPPC2, VASP, TRAPPC3, CREBBP, CPSF6, TOR1A, H3F3A, EIF2AK3, NUP153, PILRB, RPL3L, SETX, VIL1, COL1A2, SYNJ1, ARPC2, AHCTF1, CLTA, USP39, CLYBL, PPP6C, CHAF1A, C1QBP, NUP62, TMED2, SNAP29, RBM5, ATPAF2, FGA, PDCD6IP, TBP, KCND1, FCER1G, ATPIF1, FGG, CKAP5, TAPBP, DDB1, ALDH5A1, RAD51C, NDUFS7, TRAPPC6B, NDUFS6, POLR1E, VAMP4, CHMP6, ALDOA, SLU7, ITGB3BP, MCM2, COLEC12, NDUFB7, HIST1H2BO, HIST1H2BJ, HDAC1, NLRC4, HSD17B8, TM9SF4, NAPG, HLA-DMA, RXRA, HLA-DMB, RBBP5, CCL5, UBN1, STX5, BID, RRM1, NDUFA7, NUBPL, RPL23A, GTF2H4, CENPF, MARCKS, IMPDH2, TAF7, CCDC65, CENPP, SEC24C]
GO:0007264;small GTPase mediated signal transduction;6.0;0.7369933605727446;0.6916169928765168;8.741221057491218;26.42836680105094;4.015022244900292;8.845336528452411E-4;0.5284487369119741;[RAB3B, NCKAP1, CDKN1A, ROCK2, DOCK8, RASGRP4, RAB21, RAB43, RAP1B, ABR, DOCK11, RHOT1, RAB20, RRAS, ARHGDIB, CFL1, RAB6A, RAB8B, KSR1, RAB27B, VAV1, RAB11A, COL1A2, ALS2, RAB18, ELMO1, TAX1BP3, KRAS, DOCK2, KPNB1]
GO:0042264;peptidyl-aspartic acid hydroxylation;9.0;0.9326813400603323;0.8625812952104552;9.574457031221845;309.91140740841894;9.083926447120524;0.010372455903800976;0.8607930461318132;[HIF1AN]
GO:0042265;peptidyl-asparagine hydroxylation;9.0;0.9326813400603323;0.8625812952104552;9.574457031221845;309.9855153805729;9.777073627680469;0.010374936230936124;0.896240625180289;[HIF1AN]
GO:0007268;chemical synaptic transmission;7.0;0.7369933605727446;0.7194160455435727;8.663443356448536;23.173347188538074;3.922001705478042;7.755910757418987E-4;0.5514907148670789;[ALS2, VDAC3, MBP, NPTX1, SNCB, APBA3, SPG11, KCNK3, NTSR1, PAFAH1B1, GLS]
GO:0045652;regulation of megakaryocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.9575807315309;5.845247994956144;0.0023079481692908138;0.6498456195510879;[HDAC1, RBBP5, H3F3A, EP300, CIB1, THBS1]
GO:0045773;positive regulation of axon extension;11.0;0.8933024483968273;0.8790801765280758;9.582004236857228;1257.908905926367;6.113511981550823;0.04210107903683872;0.7450742393735527;[RUFY3, ADNP, RAB11A, PAFAH1B1]
GO:0007265;Ras protein signal transduction;7.0;0.7586651285174919;0.7302519295159464;8.935377071932177;27.526979089716047;4.2636448815154875;9.213032174599934E-4;0.5689623627776663;[RAB3B, NCKAP1, CDKN1A, KSR1, ROCK2, RAB27B, RAB11A, RAB21, RAB43, RAP1B, RHOT1, COL1A2, RAB20, ALS2, RRAS, ARHGDIB, CFL1, RAB18, ELMO1, TAX1BP3, KRAS, RAB6A, KPNB1, RAB8B]
GO:0007266;Rho protein signal transduction;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;29.60642063139588;5.334422371190153;9.9090025448413E-4;0.6478026081386739;[RHOT1, COL1A2, ROCK2, ARHGDIB, CFL1, TAX1BP3]
GO:0042147;retrograde transport, endosome to Golgi;6.0;0.8653626801206646;0.7558016526504768;9.36615998802463;84.48667651462847;5.311165509025885;0.0028276930298722367;0.5947335637161829;[TMEM87A, GOSR1, STX5, VPS26B, RAB6A, PLEKHJ1]
GO:0045779;negative regulation of bone resorption;7.0;1.0;0.8509193652572005;9.628524252492122;83.00611842489866;7.292166977892469;0.002778140083024753;0.7238411236270654;[IL6, CSK]
GO:0046627;negative regulation of insulin receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;294.34753946768484;6.311337724880743;0.009851547250396369;0.6736814700148209;[RELA]
GO:0042149;cellular response to glucose starvation;7.0;0.8933024483968273;0.7975705894556142;9.503361109538115;115.90251486529202;6.063501560976162;0.003879152867050031;0.6610071170671804;[BECN1, TBL2, EIF2AK3, PIK3C3, CPEB4]
GO:0045899;positive regulation of RNA polymerase II transcriptional preinitiation complex assembly;13.0;1.0;0.9625549647676366;9.628524252492122;4139.882247394957;7.379178354882098;0.13855813316817636;0.8399264890031939;[PSMC1]
GO:0032438;melanosome organization;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;22.01435712052086;6.558197802812269;7.368007211887049E-4;0.6585068532133508;[AP1G1, LYST]
GO:0001954;positive regulation of cell-matrix adhesion;6.0;0.8653626801206646;0.7558016526504768;9.34084218004034;50.25702962731741;5.926926025970411;0.0016820575532361247;0.6262235851885184;[SFRP1, PLEKHA2, CIB1, EPHA1, LIMS1]
GO:0033523;histone H2B ubiquitination;11.0;0.9326813400603323;0.8987696223598284;9.587702257971866;343.5530125033966;7.474488534686424;0.011498410150850943;0.8146746435927894;[RNF20, DTX3L]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[ANKRD17, MAP3K3, UBE2I, ZDHHC13, RELA, AKAP13, CD4, TFG, TNIP2, UBD, NUP62, RIPK1, CCL19, ECT2, TRIM32]
GO:0045786;negative regulation of cell cycle;5.0;0.5089359064165209;0.5447089650691808;7.0970975870692286;42.34575940812408;3.5270983854209863;0.0014172744586806725;0.47061698731819834;[CDKN1C, BTG2, CDKN1A, ZWILCH, MAX, CCNF, GMNN, THBS1, PPM1G, GPR132, RPS6KA2, RAD21, TPR, TP53INP1, TP53BP2, CASP2, EP300, FBXO5, E2F7, E2F8, DACT1, FANCI, TIPIN, INTS3, MAD2L1BP, CNOT10, PRKAB1, ERN1, CDK9, CNOT6, CENPF, STAG2, ESPL1, TFDP2, FAP, CNOT1, CTDSP2, TIMELESS, CNOT8, PRR11, EIF4G2, EZH2, MAD2L1]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[DIABLO, BAG3, EYA2, MKNK2, CASP2, G0S2, CIB1, RIPK1, TNFRSF10A, BID]
GO:0038095;Fc-epsilon receptor signaling pathway;8.0;0.9326813400603323;0.8413406700301662;9.5544162803384;78.4757768553383;4.989581884898423;0.002626513627734276;0.6301674496329921;[FCER1G, LCP2, CALM1, NFKB1, VAV1, RELA]
GO:0008203;cholesterol metabolic process;6.0;0.7980440201809971;0.722142322680643;9.223059144383958;82.64786032185484;5.058574756385375;0.0027661495067272364;0.581816060879476;[HSD3B7, RXRA, SNX17, SCAP, ERLIN2, APOL1, SCARF1, NFE2L1]
GO:0046513;ceramide biosynthetic process;8.0;0.811012628672052;0.780506314336026;9.474373572664863;443.75121156962103;6.015873511986907;0.014851953701072812;0.6826520511697386;[UGT8, DEGS1]
GO:0021897;forebrain astrocyte development;6.0;1.0;0.8231203125901445;9.628524252492122;34.09911675737102;9.083926447120524;0.001141266750656509;0.7876727335416686;[KRAS]
GO:0043488;regulation of mRNA stability;9.0;0.7436939687323844;0.7680876095464813;9.240758721483358;282.23354693635815;4.989581884898423;0.009446102822258332;0.6514080748132811;[FXR1, UPF1, XRN1, YTHDF3, DCP1A, TNPO1, YWHAZ, DCP2]
GO:0045663;positive regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;6.7325511899570465;0.00382428925936973;0.6674232935401965;[FLT3LG, HIF1AN]
GO:0043124;negative regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.487551390376;6.063501560976162;0.008015432820232688;0.6850877518099798;[NLRP12, OTUD7B, RORA, RIPK1, TANK]
GO:0038096;Fc-gamma receptor signaling pathway involved in phagocytosis;10.0;1.0;0.9152410118609203;9.628524252492122;384.64074149301706;4.886724499458715;0.01287357946357817;0.6651483300191682;[NCKAP1, ACTR2, ARPC2, WIPF2, ARPC1A, ELMO1, NCKAP1L, VAV1]
GO:0043248;proteasome assembly;6.0;0.8653626801206646;0.7558016526504768;9.310070521373587;44.51706700895919;7.138016298065211;0.0014899461700306506;0.6881587980249038;[PSMD8, PSMD4]
GO:1901800;positive regulation of proteasomal protein catabolic process;10.0;0.7763722522362496;0.8034271379790452;9.430698509162202;1662.1011242697743;5.104244793218563;0.05562902883541267;0.6762723279577749;[ZFAND2A, EDEM1, PSMC1, UBQLN1, RAD23A, SIRT2]
GO:0048814;regulation of dendrite morphogenesis;10.0;0.8259837884571596;0.8282329060895002;9.533214072687796;153.5143611256957;5.334422371190153;0.0051379875129217364;0.6880436199995941;[RAB21, FXR1, ACTR2, CFL1, LRP8, PAFAH1B1]
GO:0043129;surfactant homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;28.07196958697662;7.474488534686424;9.395435589437007E-4;0.7331650565203278;[CTSH, ABCA12]
GO:0097067;cellular response to thyroid hormone stimulus;6.0;0.8933024483968273;0.7697715367885581;9.485423408851448;110.48347060425422;7.004484905440688;0.003697782332456301;0.6813299963962409;[CTSH]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[FCER1G, ITGB3, ITGA2, ITGB2, NEDD9, CCM2, VAV1]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[CIITA, CDKN1A, CD80, ITGB2, IL5RA, CIB1, RORA, LRP8, RELA, IL22RA2, RAP1B, CCL5, CFL1, IL21R, NCAM1, RIPK1, CCL19, HLA-DQA1, CCR2, HLA-DPA1, IFNAR2, BBS2, MAP3K3, IL4R, CCL20, FLT3LG, TNFRSF10A, HLA-A, HLA-F, YWHAZ, NFKB1, VAV1, NFKBIA, CD4, IL6, COL1A2, KARS, IL23A, TNIP2, HLA-DPB1, SDC1, PSME2, KRAS, LCP1, HLA-DRB3, LIMS1]
GO:1990668;vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;65.8060249050737;7.9853141584524145;0.0022024684319953925;0.7592887026755414;[TAPBP]
GO:0016197;endosomal transport;5.0;0.7090535922965819;0.6447678080092112;8.817594036275793;47.18803257139101;4.463867648638682;0.0015793409836922997;0.5185234110033771;[TMEM87A, GRIPAP1, GOSR1, CLEC16A, VPS26B, LYST, RAB11A, ALS2, SNX17, STX5, CHMP4B, CHMP6, RAB6A, VPS16, PLEKHJ1]
GO:0030242;autophagy of peroxisome;5.0;0.8933024483968273;0.736892236059334;9.405380701177911;39.83166466328102;8.16763571524637;0.0013331299701091492;0.7079342821725234;[PIK3C3]
GO:0031333;negative regulation of protein complex assembly;6.0;0.620063164412167;0.633151894796228;8.03928904737554;78.76701431095417;4.925043363760852;0.0026362610832770463;0.5749872592508131;[VIL1, TRIM9, EP300, VDAC2, TFIP11, MAPRE1, SPTB, EML2, SIRT2, DACT1]
GO:0010634;positive regulation of epithelial cell migration;8.0;0.7866048967936545;0.7683024483968273;9.383401794459138;242.52723865374625;4.901876304479318;0.00811716841739676;0.6256821821716325;[VIL1, MAP3K3, SP1, ROCK2, ITGB3, ITGA2, CTSH, CIB1, THBS1, CLASP1, RAB11A, HBEGF]
GO:0071712;ER-associated misfolded protein catabolic process;9.0;1.0;0.896240625180289;9.628524252492122;305.4386451462502;7.212124270218933;0.010222756576110884;0.7650689957573628;[TOR1A]
GO:0048709;oligodendrocyte differentiation;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;23.145667324477426;6.518977089658987;7.746646556020492E-4;0.623621803389518;[SOX8, TSPAN2, CSK]
GO:0009303;rRNA transcription;11.0;0.8436909121759173;0.8542744084176208;9.510741216835738;822.3157603842984;6.8867018697843045;0.027522168463925335;0.7846152062148197;[MARS]
GO:0000723;telomere maintenance;7.0;0.7307253602413294;0.7162820453778652;9.292052015870908;183.01793442924338;5.266214121163619;0.006125445559899373;0.6202338003175094;[UPF1, FEN1, DCLRE1C, RAD51C, XRCC5, TFIP11, SMG5, ZNF365]
GO:0038083;peptidyl-tyrosine autophosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;522.6399477532146;5.905872616772578;0.017492288705884526;0.7172676121338334;[FES, CSK]
GO:0006275;regulation of DNA replication;7.0;0.6144040707577935;0.6581214006360973;8.623002386890024;150.73814970462044;5.142344639450834;0.005045070215086414;0.6138991092621975;[ANKRD17, TIPIN, FBXO18, GMNN, WRNIP1, SENP2, PPP2CA, STAG2, MSH3, TIMELESS, E2F7, ZNF365, E2F8]
GO:0048820;hair follicle maturation;4.0;1.0;0.75;9.628524252492122;22.57030317957519;7.8311634786251565;7.554077354662837E-4;0.6504860644832351;[TRPC4AP]
GO:0007249;I-kappaB kinase/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;5.602686357784832;8.845336528452411E-4;0.6096419534788213;[NFKBIA, IRAK1BP1, NKIRAS1, ROCK2, TNIP2, TIFA, BCL3, SNIP1, RIPK1, TANK, NFKB1, RELA]
GO:1902902;negative regulation of autophagosome assembly;9.0;1.0;0.896240625180289;9.628524252492122;476.81513928252696;7.292166977892469;0.015958573606020727;0.769162383550154;[BECN1, CHMP4B]
GO:0001934;positive regulation of protein phosphorylation;9.0;0.5833093054345528;0.6878952778975655;8.604019935977734;663.1129447749842;2.9039097934679514;0.02219379349871355;0.5447467070638558;[CDKN1A, NCF1, ITGB3, CD80, CIB1, FLCN, AKAP13, ARL6IP5, FGA, FBXO18, KSR1, SPHK1, FGG, PLAUR, ZFP91, FLT3LG, OXSR1, SENP2, GFRA2, ERN1, TWSG1, KARS, ALS2, IL23A, JTB, LCP2, ADNP, EPHA1, ARHGEF5, HBEGF, HDAC3, ROCK2, LRP8, THBS1, STK3, C3, RAP1B, PPP2CA, CCL5, DVL3, NCKAP1L, RIPK1, CSK, ZNF622, CCL19, ECT2, MARK2, TBX1, MAP3K3, PDE6H, CCL20, XRCC5, TNFRSF10A, PILRB, CDK9, CD4, IL6, CDK2AP1, KRAS, CAMK1, CALM1, CALM2, EZH2]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[FCER1G, CCL20, CCL5, ITGB2, NCKAP1L, CCL19, VAV1]
GO:0018125;peptidyl-cysteine methylation;9.0;0.9326813400603323;0.8625812952104552;9.582004236857228;367.81618772121425;8.67846133901236;0.01231047678995128;0.8400575416471059;[RAB3B, RAB6A]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[HSD3B7, GYPA, FCER1G, WDR1, CCL20, DOCK8, ITGB3, ITGB2, SIRPG, TNFRSF10A, LYST, GLG1, VAV1, NLRP12, IL6, COL1A2, CCL5, SDC1, NCKAP1L, CCL19, CD244, ARHGEF5, CCR2]
GO:0030111;regulation of Wnt signaling pathway;6.0;0.5902001590945054;0.6182203921373972;7.99439372746765;41.8512380110395;4.069963362931594;0.0014007232725606145;0.5312584282431182;[TLE4, CSNK2A1, HDAC1, KLHL12, SENP2, APCDD1, NFKB1, ARNTL, STK3, PPP2CA, DEPDC1B, SFRP1, RNF213, TBL1XR1, GNAQ, DVL3, TAX1BP3, DACT1]
GO:0017158;regulation of calcium ion-dependent exocytosis;9.0;0.6799073451904818;0.73619429777553;8.730582659286164;63.43514412564899;5.514393750639154;0.0021231171859622203;0.6782469780335098;[RAP1B, TRIM9, SYTL3, RAB3GAP1]
GO:0090207;regulation of triglyceride metabolic process;6.0;0.7866048967936545;0.7164227609869718;9.223059144383958;42.304786856758916;6.280566066213989;0.0014159031442593827;0.6443087532925187;[C3, TBL1XR1]
GO:0010884;positive regulation of lipid storage;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;46.19953359410991;6.686031174322154;0.0015462568125140237;0.665044257777226;[C3, OSBPL11, NFKB1]
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[ERN1, CDKN1C, CDKN1A, FAP, TP53INP1, PRR11, THBS1, PRKAB1, EIF4G2, PPM1G]
GO:0070926;regulation of ATP:ADP antiporter activity;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;150.82582522695972;9.777073627680469;0.005048004635916263;0.875;[RIPK1]
GO:0007171;activation of transmembrane receptor protein tyrosine kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1143.6879814690685;7.212124270218933;0.03827820748741112;0.8169486831672182;[PILRB]
GO:0008380;RNA splicing;8.0;0.7248374789738407;0.7374187394869203;9.182237149863703;117.47952805794706;3.8501476017100584;0.003931934079388465;0.5718967274016261;[SF3B5, SF3B2, WBP4, DDX42, DDX41, CASC3, USP39, SUPT6H, EFTUD2, PPP2CA, PABPN1, PCF11, U2AF2, POLR2B, C1QBP, ARL6IP4, SNRPB2, POLR2G, ZNF326, SMNDC1, RBM5, AQR, GPKOW, WTAP, BUD31, CPSF2, TFIP11, THOC2, LSM5, SRRM1, ERN1, SON, PRPF3, SNRPG, CD2BP2, SLU7]
GO:0045727;positive regulation of translation;8.0;0.6634067003016617;0.7067033501508309;9.123968241739727;1032.6861465930526;5.104244793218563;0.03456307596927652;0.6360313160968547;[FXR1, RPS9, IL6, RXRA, YTHDF3, ITGA2, C1QBP, CCL5, BCL3, POLR2G, THBS1]
GO:0030073;insulin secretion;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;236.67564318465372;6.166155715036245;0.007921320783140251;0.711578115202808;[GAL, SNX19]
GO:0032495;response to muramyl dipeptide;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;59.66765988983927;7.004484905440688;0.0019970228791053504;0.6813299963962409;[NFKBIA, RELA]
GO:0045841;negative regulation of mitotic metaphase/anaphase transition;11.0;0.8436909121759173;0.8542744084176208;9.5544162803384;1557.3872016210385;6.7325511899570465;0.052124348080771515;0.7767319332797141;[CENPF, RAD21, TPR, MAD2L1]
GO:0051291;protein heterooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;5.113634533568402;0.00140677858073304;0.5846318204451575;[RRM1, CPSF6, COL1A2, NUP62, RIPK1, IKZF1, HSD17B8, PRKAB1]
GO:0000413;protein peptidyl-prolyl isomerization;9.0;0.9326813400603323;0.8625812952104552;9.571365838652174;156.19170532668662;6.039404009397101;0.005227595813875556;0.705096027081865;[PPID]
GO:0097051;establishment of protein localization to endoplasmic reticulum membrane;8.0;1.0;0.875;9.628524252492122;143.8803684663336;8.67846133901236;0.004815546448643375;0.8188169164668168;[RAB3GAP2, RAB3GAP1]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[ERRFI1, RABGAP1, DOCK8, RIC8A, ABR, DOCK11, ARHGAP21, RGS1, CCL5, ARHGDIB, DVL3, NCKAP1L, EVI5L, CCL19, ECT2, A2M, TBC1D22A, STARD13, CCL20, TBC1D8, ARHGAP25, VAV1, BCR, DEPDC1B, SFRP1, ALS2, GNAQ, RAB3GAP2, PKP4, TAX1BP3, DOCK2, EPHA1, ARHGEF5, RAB3GAP1, EZH2, LIMS1]
GO:0051168;nuclear export;7.0;0.6729672293956388;0.6874029799550199;8.529911963824013;33.8974465615721;4.665085839323926;0.001134517030694512;0.5894920720289035;[UPF2, UPF1, SMG1, AHCYL1, SEH1L, CPSF2, NUP153, THOC2, CASC3, SMG5, SRRM1, AKAP13, ALKBH5, NXF3, PABPN1, U2AF2, TPR, NUP62, NUP43, SLU7, RAE1]
GO:0001866;NK T cell proliferation;8.0;0.9326813400603323;0.8413406700301662;9.56398573135455;102.50086820772104;9.083926447120524;0.0034306118141200753;0.839552420951524;[ELF4]
GO:0010458;exit from mitosis;5.0;1.0;0.7902410118609202;9.628524252492122;29.819065850336454;7.379178354882098;9.980172985937987E-4;0.6676125360964777;[SPAST, CHMP4B, CLASP1]
GO:0032486;Rap protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;7.379178354882098;9.9090025448413E-4;0.7523715242355574;[RAP1B]
GO:0032007;negative regulation of TOR signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.487551390376;5.926926025970411;0.008015432820232688;0.6781032725983739;[FLCN, DDIT4, ARNTL]
GO:0007062;sister chromatid cohesion;5.0;0.7508913569872202;0.6656866903545304;8.801845679307654;32.565640385727406;6.113511981550823;0.001089942676536732;0.6028862989048107;[NIPBL, STAG2, RAD51C, RAD21]
GO:1904385;cellular response to angiotensin;8.0;1.0;0.875;9.628524252492122;462.69925393661634;7.379178354882098;0.015486127626965131;0.7523715242355574;[NFKB1, RELA]
GO:0090305;nucleic acid phosphodiester bond hydrolysis;6.0;0.6073376606709605;0.6267891429256247;8.355558576679234;112.24841944109592;4.100319825412187;0.0037568535816745637;0.5328108591460956;[FEN1, DFFA, DCLRE1C, CPSF6, REXO1, FBXO18, CPSF2, RNASE3, GTF2H4, SMG5, SND1, ERN1, DDB1, CNOT6, PAN3, XRN1, LAS1L, CNOT1, PCF11, RPP21, CNOT8, DCP1A, DCP2, KPNB1]
GO:0045616;regulation of keratinocyte differentiation;7.0;0.8259837884571596;0.7639112594857803;9.461470167828956;71.48722327515921;6.113511981550823;0.002392613028695569;0.663564652301091;[ERRFI1, ROCK2, GRHL1]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[OXTR, AHCYL1, SUCNR1, ROCK2, DGKA, DEFB1, IQGAP2, CRHR1, RIC8A, HEBP1, C3, ABR, AKAP13, GPR132, GNG2, GNAT2, RGS1, TBXA2R, ADORA3, CCL5, NPPA, OR56B1, CCL19, ECT2, NTSR1, CCR2, SPHK2, CCL20, SPHK1, TSHR, VAV1, SFRP1, GAL, GNAQ, GNB2, NMUR1, CALM1, DAGLB, CALM2, ARHGEF5]
GO:0030182;neuron differentiation;4.0;0.5833093054345528;0.5416546527172764;7.212610474191073;21.066225782797595;4.296434704338478;7.050676185779127E-4;0.4697198705845162;[MTPN, PPP1CC, SFRP1, HERC1, ROM1, DDIT4, RORA, SOX8, ATP7A, IER2, RUNX2, PAFAH1B1]
GO:0008033;tRNA processing;9.0;0.6007507099811141;0.6966159801708461;8.495425787752843;356.94625997820395;4.973052582947213;0.011946670090692574;0.6505627655428052;[KARS, RPP21, ADAT1]
GO:0032481;positive regulation of type I interferon production;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;65.23665507211369;5.618190544320798;0.002183412136085803;0.610434838299289;[CREBBP, POLR3C, XRCC5, EP300, DDX41, LRRFIP1, TMEM173, NFKB1, RELA]
GO:0032482;Rab protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;5.500407508664414;9.9090025448413E-4;0.6562910957882058;[RAB21, RAB3B, RAB43, RAB20, RAB18, RAB27B, RAB6A, RAB11A, RAB8B]
GO:0045732;positive regulation of protein catabolic process;7.0;0.7043150770688792;0.7030769037916401;9.033817144745429;231.0521549826792;4.39257856489138;0.0077331076938309705;0.5755560373415389;[CSNK2A1, ZFAND2A, EDEM1, ATPIF1, RAD23A, SIRT2, DDB1, ITCH, GGA3, PSMC1, VPS11, UBQLN1, STX5, TRIM32, DACT1]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[SERPINA3, CSTB, PDXK, SIGLEC9, CLEC12A, ITGB2, UBR4, IQGAP2, C3, RAP1B, HK3, PSMD7, PSMD2, PSMB1, LAMP2, CTSH, NCKAP1L, GUSB, RAB6A, SNAP29, ACTR2, SERPINB1, TMEM30A, FCER1G, XRCC5, HSPA6, PLAUR, COMMD3, RNASE3, TMEM173, LILRB3, UNC13D, NFKB1, SERPINB6, IMPDH2, RAB18, PTX3, MNDA, DEGS1, DOCK2, ALDOA, KPNB1]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[NFKBIA, KARS, RIPK1, TNFRSF10A, RELA, LIMS1]
GO:0001755;neural crest cell migration;6.0;0.7980440201809971;0.722142322680643;9.089527751759436;22.57397290845719;5.825829909099042;7.555305579894227E-4;0.6210535250702663;[TBX1, SEMA6B, CFL1, SOX8]
GO:0045860;positive regulation of protein kinase activity;10.0;0.6281612110245125;0.7293216173731766;9.003430535177193;1094.9224192180604;3.5309668621989068;0.03664606800502658;0.5958148214005239;[CDKN1A, NCF1, ITGB3, CIB1, LRP8, THBS1, STK3, PPP2CA, AKAP13, CCL5, DVL3, NCKAP1L, RIPK1, CSK, CCL19, ECT2, MARK2, MAP3K3, PDE6H, XRCC5, ZFP91, TNFRSF10A, PILRB, OXSR1, ERN1, CD4, KARS, ALS2, IL23A, JTB, LCP2, KRAS, CAMK1, ADNP, CALM1, CALM2, ARHGEF5, EZH2]
GO:0035509;negative regulation of myosin-light-chain-phosphatase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1252.1557676251311;8.16763571524637;0.04190852667538468;0.8501222226412654;[ROCK2, NCKAP1L]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CMTM7, ERRFI1, COPA, UBE2I, NCF1, CCL20, BUD31, FLT3LG, IL6, GAL, IL23A, CCL5, NPPA, FAM3C, CCL19, CHMP6, KCNK3, HBEGF]
GO:0033206;meiotic cytokinesis;5.0;0.8436909121759173;0.712086467948879;9.176539128749065;36.66109544223591;7.9853141584524145;0.0012270138716078147;0.6986103492792611;[ACTR2]
GO:0035984;cellular response to trichostatin A;6.0;1.0;0.8231203125901445;9.628524252492122;367.2586666355552;8.390779266560578;0.012291817060950673;0.7522251544931926;[ACTR2, EZH2]
GO:0090307;mitotic spindle assembly;8.0;1.0;0.875;9.628524252492122;186.05212215721153;6.193554689224359;0.006226997092562797;0.6917386748366816;[TUBGCP2, KPNB1, CLASP1, RAB11A]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[VIL1, MKLN1, CFDP1, WDR1, EPB41, FES, WIPF2, LST1, ITGB2, VRK2, ALDOA]
GO:0007032;endosome organization;5.0;0.8436909121759173;0.712086467948879;9.223059144383958;20.915744831851537;5.528578385631111;7.000311565738116E-4;0.5729727676072827;[VPS18, PDCD6IP, ALS2, VPS33B, VPS11, CHMP4B, PIK3C3, CHMP6, RAB11A, PLEKHJ1]
GO:0008361;regulation of cell size;5.0;0.7763722522362496;0.6784271379790451;8.999915593069748;28.02071028012121;5.54296712308321;9.378279560736312E-4;0.5737086083097278;[MTPN, ATP7A, CLCN3, VAV1]
GO:0043200;response to amino acid;5.0;0.6441938053840475;0.612337914552944;8.412128928167629;56.712201515420396;5.104244793218563;0.0018981063470534028;0.5512723279577749;[COL1A2, CFL1, PIK3C3, ATP7A, RELA, CPEB4]
GO:0043323;positive regulation of natural killer cell degranulation;11.0;1.0;0.9324289523296623;9.628524252492122;1142.356041613066;9.083926447120524;0.03823362865909877;0.8969813732811862;[AP1G1]
GO:0042355;L-fucose catabolic process;8.0;1.0;0.875;9.628524252492122;210.4172434324934;7.57984905034425;0.007042475774460966;0.7626338329336335;[FUT4]
GO:0043201;response to leucine;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;59.7079337889743;7.292166977892469;0.001998370810265244;0.6960420709600095;[PIK3C3]
GO:0045746;negative regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;188.1075192762445;6.193554689224359;0.006295789384399518;0.6676580400938822;[NFKBIA, HIF1AN]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[ITIH2, PRKCSH, SERPINA10, CCNF, NEDD8, MSLN, PSMB10, PSMA7, PSMD8, C3, TGOLN2, PSMD7, PSMD4, RBBP5, PSMD2, UBD, PSMB1, SKP2, APOL1, FGA, KLHL25, IGFBP5, FGG, FBXL15, FBXL16, RAB11A, DDB1, IL6, COPS5, PSMA1, PSMC1, PSME2, FBXL3]
GO:0001842;neural fold formation;6.0;1.0;0.8231203125901445;9.628524252492122;64.32556344156964;8.67846133901236;0.0021529187191407268;0.7669372290569613;[CFL1]
GO:0035617;stress granule disassembly;6.0;1.0;0.8231203125901445;9.628524252492122;96.99997869907772;8.67846133901236;0.0032465019927449285;0.7669372290569613;[KLC1]
GO:0032465;regulation of cytokinesis;6.0;0.5930994877375815;0.6196700564589352;8.140447197062288;31.798591743249187;5.358233019883872;0.0010642702487719462;0.5971405984103235;[BECN1, AHCTF1, RAB11A, FLCN, SPAST, NUP62, PKP4, PIK3C3, CALM1, ECT2, CALM2, E2F7, E2F8]
GO:0030043;actin filament fragmentation;8.0;1.0;0.875;9.628524252492122;62.21554848606067;8.390779266560578;0.002082298417470015;0.8041048419030481;[WDR1, CFL1]
GO:0035735;intraciliary transport involved in cilium assembly;8.0;1.0;0.875;9.628524252492122;77.80597868627544;6.088194173566533;0.0026040960857949586;0.6863505331661754;[IFT122, TNPO1, DYNLL2, CLUAP1]
GO:0033673;negative regulation of kinase activity;9.0;0.6519675769143192;0.7222244136374487;8.892817457513381;266.5566888017255;4.174954806800768;0.008921412488748512;0.6097480081553338;[CDKN1C, ERRFI1, CDKN1A, CIB1, DUSP14, PPP2CA, SFRP1, PIK3IP1, GNAQ, PKIA, NUP62, STK38, TAF7, CSK, EPHA1, CHMP6]
GO:1903061;positive regulation of protein lipidation;9.0;0.9326813400603323;0.8625812952104552;9.596775554177542;1090.8429565037068;8.390779266560578;0.036509532059255244;0.8253454670833372;[RAB3GAP2, RAB3GAP1]
GO:0032228;regulation of synaptic transmission, GABAergic;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;30.61939422688933;6.311337724880743;0.001024803569108247;0.6736814700148209;[USP46, OXTR, KRAS]
GO:0010796;regulation of multivesicular body size;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;28.02071028012121;8.67846133901236;9.378279560736312E-4;0.7669372290569613;[RAB11A]
GO:0034645;cellular macromolecule biosynthetic process;5.0;0.47227530599134737;0.526378664856594;6.914431736933949;102.76050904336213;1.783791299578878;0.003439301759227401;0.38146418187616277;[RPL3, GFI1, IKZF1, IKZF2, ELK1, UBE2L3, RPL36AL, SAP130, ZXDC, DPF2, TRIM24, SOX8, IER5, IER2, SAP30BP, CSNK2A1, ZNF282, MRPS18A, SND1, EID1, EWSR1, RFX4, HOXB4, ZNF276, ZNF395, ZNF394, FOXG1, ZNF20, MRPL17, RPAP1, RAD21, HLTF, HIVEP1, HESX1, HIVEP2, ZNF264, ZNF260, XRCC5, INTS3, PBX3, FLI1, RPL3L, SOX30, ZNF30, INTS4, EZH2, CPEB4, PHF3, SETD5, HBS1L, FEN1, BTG2, ELL, INTS10, ATF7IP2, HOXC13, SMG5, NIPBL, ZMYM2, SCML1, CHAF1A, MRPL40, C1QBP, ZNF485, UPF1, TSC22D4, MRPS24, NCOA6, MRPS22, COMMD3, BAZ1A, PPRC1, ZFX, MED29, SIRT2, MED28, TFEC, VGLL4, ZNF350, MRPS36, ZNF69, RELA, ARNTL, EXTL2, SERTAD3, GPBP1L1, RPL19, ZNF462, NFYC, ATAD2, GRHL1, GTF2H4, PER2, CENPF, GFI1B, NFIB, NFIC, MARS, ZNF696, NAB1, ARID4A, EFTUD2, YY1, EP300, ZNF326, ZNF688, ZNF564, GTF2I, TLE4, ZNF441, RPS9, WRNIP1, ERN1, ILF3, ZNF93, TBL1XR1, TIMELESS, ADNP, ZNF550, MAX, RLF, SUPT6H, GTF2E2, ZNF549, ZNF548, NLRP3, SUDS3, ZNF544, TRAPPC2, TFAP2A, DR1, CNOT10, NFKB1, CDK9, CNOT6, IRAK1BP1, TFCP2, COPS5, CNOT1, SP1, SP3, MAFF, BCL3, ZNF658, NFE2L3, CNOT8, TMEM18, ZNF532, ZNF410, EIF4G2, NFE2L1, CIITA, ONECUT2, CHD1, AFF4, POLB, LBH, ZNF407, NUP62, ZNF768, ZNF525, LRRFIP1, HIF1AN, ATP7A, KLF12, TBP, KLF13, BUD31, ARNT, SAFB, ARID1A, CREB3, ZNF519, TFDP2, ELF4, LCOR, ZNF630, ITGB3BP, MCM2, SMARCD2, HDAC3, HDAC1, WBP2, RRBP1, POLR2B, RBBP5, TP53INP2, FAM120B, TP53INP1, TAF1A, POLR2G, ASCC3, E2F7, ZNF189, E2F8, TBX1, POLR2J3, RRM1, NDUFA7, CHURC1, EYA2, RPL23A, ARID3B, DEK, USF2, POLE4, POLR3C, TNIP2, POLR3E, TAF7, CDK2AP1, MNDA]
GO:0035970;peptidyl-threonine dephosphorylation;8.0;1.0;0.875;9.628524252492122;179.24922260518233;7.004484905440688;0.005999310166768488;0.7332096838060964;[PPP2CA, PPM1G]
GO:0086023;adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart process;11.0;0.8436909121759173;0.8542744084176208;9.466005322994347;115.20692759691805;8.390779266560578;0.003855872187165453;0.8615337942327104;[AKAP13]
GO:0007286;spermatid development;5.0;1.0;0.7902410118609202;9.628524252492122;72.7828096339012;5.370354380416217;0.0024359751381706407;0.5648811846224242;[SPAG6, H3F3A, CIB1, AFF4, IQCG]
GO:0030163;protein catabolic process;5.0;0.6347111282356054;0.607596575978723;8.35223078658656;135.66522553384723;3.7109655375767217;0.004540593007841691;0.48001996203013964;[CCNF, CLTA, PSMD8, TRIM9, PSMD7, PSMD4, PSMD2, CDC26, LAMP2, TRIM24, SKP2, CTSE, C18orf25, FBXO18, RAD23A, KCTD5, SIRT2, DDB1, PSMA1, KCTD10, TBL1XR1, ANAPC5, MAN1B1, RNF38, DERL2, PSMB10, PSMA7, ANAPC11, ARNTL, PSMB1, UBQLN1, RIPK1, RFFL, UBE2I, TOR1A, LRRC29, UBE2B, KLHL25, AMBP, EDEM1, SYVN1, FBXL15, LNPEP, ERLIN2, FBXL16, PGA3, PGA5, KBTBD4, NSFL1C, ITCH, PSMC1, FBXL3, TPP1, MAD2L1]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[VIL1, CIB1, RAB11A]
GO:0051085;chaperone cofactor-dependent protein refolding;5.0;1.0;0.7902410118609202;9.628524252492122;21.14140270213274;6.409777797693995;7.075837224132252E-4;0.618037346520142;[TOR1A, HSPA6, HSPE1]
GO:0007169;transmembrane receptor protein tyrosine kinase signaling pathway;7.0;0.579397892394798;0.6406183114545996;7.564831067780425;28.111912685638995;3.5644675319289507;9.408804185094754E-4;0.533206400604739;[NCKAP1, NCF1, ROCK2, ITGB3, ARPC1A, NEDD9, RASGRP4, TIAL1, SGPL1, POLR2B, POLR2G, NCKAP1L, CSK, ATP6V1F, FAM83A, ACTR2, CAMLG, EIF2AK3, PILRB, PILRA, GFRA2, SIRT2, VAV1, SETX, BCR, VIL1, CD4, SLC9A6, ARPC2, CD8B, PTPRA, FES, DDIT4, ELMO1, LCP2, EPHA1, HBEGF]
GO:0045630;positive regulation of T-helper 2 cell differentiation;13.0;1.0;0.9625549647676366;9.628524252492122;2538.1941708228874;7.8311634786251565;0.08495107467099283;0.8630410292508717;[IL4R, NLRP3]
GO:0044546;NLRP3 inflammasome complex assembly;6.0;1.0;0.8231203125901445;9.628524252492122;44.51706700895919;9.777073627680469;0.0014899461700306506;0.8231203125901445;[NLRP3]
GO:0042247;establishment of planar polarity of follicular epithelium;5.0;1.0;0.7902410118609202;9.628524252492122;24.278965171130995;9.777073627680469;8.125951146276997E-4;0.7902410118609202;[WDR1]
GO:0045876;positive regulation of sister chromatid cohesion;9.0;0.7436939687323844;0.7680876095464813;9.292052015870908;259.00348872071737;7.474488534686424;0.008668613679475917;0.7784863164434164;[NIPBL, FEN1, RAD21]
GO:1990000;amyloid fibril formation;5.0;1.0;0.7902410118609202;9.628524252492122;65.1103285866179;7.697632086000634;0.0021791841023027143;0.6838982747154925;[RIPK1]
GO:0099578;regulation of translation at postsynapse, modulating synaptic transmission;9.0;1.0;0.896240625180289;9.628524252492122;278.44239227826074;8.67846133901236;0.00931921628766949;0.8400575416471059;[FXR1]
GO:0035729;cellular response to hepatocyte growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;78.10713999468214;7.138016298065211;0.00261417568375975;0.6881587980249038;[VIL1, SIRT2, RELA]
GO:0032212;positive regulation of telomere maintenance via telomerase;10.0;1.0;0.9152410118609203;9.628524252492122;1624.1830741800397;6.250713103064308;0.054359945822938814;0.734902770639515;[XRCC5]
GO:0032332;positive regulation of chondrocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.567899630675686;229.711107350086;6.832634648514029;0.007688224036432589;0.7003406189322132;[RUNX2, RELA]
GO:0030036;actin cytoskeleton organization;5.0;0.6347111282356054;0.607596575978723;8.048073876931273;29.6146440060229;3.9779809732199434;9.911754834323397E-4;0.49367514382642164;[NCKAP1, PDCD6IP, WDR1, EPB41, ROCK2, WIPF2, ARPC1A, BCR, VIL1, ABR, MKLN1, PARVG, CFL1, ELMO1, NCKAP1L, KRAS, DOCK2, TRIM32, ARHGEF5, PAFAH1B1]
GO:0030157;pancreatic juice secretion;6.0;1.0;0.8231203125901445;9.628524252492122;60.48885175748684;7.8311634786251565;0.0020245074318908153;0.7236063770733796;[COPA]
GO:0071902;positive regulation of protein serine/threonine kinase activity;11.0;0.6763753087927167;0.7706166067260205;9.206529842432747;1260.5827351979337;3.9422628906178643;0.04219056969626795;0.6340364598898325;[MAP3K3, PDE6H, CIB1, THBS1, STK3, ERN1, PPP2CA, AKAP13, KARS, ALS2, DVL3, RIPK1, CSK, KRAS, CAMK1, CCL19, CALM1, CALM2, ARHGEF5, EZH2]
GO:0035722;interleukin-12-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.948432231191374;0.00101047745553359;0.6551224661907153;[RAP1B, CFL1, PSME2, LCP1]
GO:0007093;mitotic cell cycle checkpoint;7.0;0.7140352122741334;0.7079369713942671;9.0094850440859;132.2042645947957;5.142344639450834;0.0044247577598742595;0.6138991092621975;[FANCI, TIPIN, CENPF, ZWILCH, INTS3, TPR, MAD2L1BP, MAD2L1]
GO:0031087;deadenylation-independent decapping of nuclear-transcribed mRNA;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;114.44564401843101;7.9853141584524145;0.0038303927109042315;0.7592887026755414;[DCP1A]
GO:0007096;regulation of exit from mitosis;8.0;0.7763722522362496;0.7631861261181248;9.249034630787218;94.90422389775904;6.8867018697843045;0.0031763589656016605;0.7271862538851576;[MAD2L1BP, SIRT2]
GO:0050718;positive regulation of interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;998.8167007681584;6.518977089658987;0.033429496098039586;0.7658097438582601;[NLRP12, NLRP7, NLRP3, CCL19]
GO:0061614;pri-miRNA transcription by RNA polymerase II;11.0;1.0;0.9324289523296623;9.628524252492122;587.6398479969114;7.57984905034425;0.019667776870928726;0.8200627852632958;[RELA]
GO:0000338;protein deneddylation;9.0;1.0;0.896240625180289;9.628524252492122;202.59641706362558;7.474488534686424;0.0067807197541817285;0.7784863164434164;[COPS5, TOR1A]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[BECN1, CREBBP, ITGA2, ITPR2, ARNT, RORA, THBS1, TM9SF4, SIRT2, NPEPPS, ALKBH5, SFRP1, TBL2, NPPA, LMNA, DDIT4, UBQLN1, EP300, SCAP, ATP7A, KCNK3]
GO:0000460;maturation of 5.8S rRNA;10.0;0.8933024483968273;0.861892236059334;9.533214072687796;358.78453946307087;6.832634648514029;0.012008195650706942;0.7646622655359331;[WDR37, LAS1L]
GO:0001787;natural killer cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;50.60132884827668;9.777073627680469;0.00169358093831245;0.8231203125901445;[ELF4]
GO:2000637;positive regulation of gene silencing by miRNA;9.0;0.8436909121759173;0.8180860812682478;9.434368238051164;125.11806367321617;6.7325511899570465;0.004187588992195782;0.740543606130341;[FXR1]
GO:0033137;negative regulation of peptidyl-serine phosphorylation;10.0;0.8933024483968273;0.861892236059334;9.56398573135455;780.3281191277907;6.518977089658987;0.026116879897493853;0.7486218033895181;[DDIT4]
GO:0050713;negative regulation of interleukin-1 beta secretion;11.0;1.0;0.9324289523296623;9.628524252492122;999.3037873052855;7.379178354882098;0.033445798446087804;0.8098004765652196;[NLRP7, NLRP3]
GO:0050714;positive regulation of protein secretion;8.0;0.6467165523344657;0.6983582761672329;8.730582659286164;381.48337166918856;4.304802954008995;0.01276790513702299;0.5951478232618299;[FGA, IL4R, FGG, GLMN, NLRP12, IL6, KARS, NLRP7, NLRP3, MBP, CCL19, CD244, PPID, EXOC1]
GO:0050830;defense response to Gram-positive bacterium;7.0;1.0;0.8509193652572005;9.628524252492122;71.44439831434403;5.334422371190153;0.0023911797157970473;0.6237219733958743;[IL6, SEH1L, HIST1H2BJ, PPP1R11, NLRP3, DEFB1, RNASE3, HIST1H2BC]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[RAB3B, NCKAP1, OXTR, DGKA, CD80, SIRPG, IL5RA, DEFB1, RAB43, DOCK11, RPS6KA2, ARHGDIB, CFL1, ARL6IP5, EP300, SNIP1, IFNAR2, IGFBP5, ERN1, BCR, DEPDC1B, KARS, DDIT4, ELMO1, KPNB1, DIABLO, CLEC16A, ITPR2, KRCC1, CRHR1, RASGRP4, STK3, RAP1B, ABR, NUAK1, RHOT1, ZMAT1, RRAS, TBXA2R, STK38, TP53BP2, DVL3, STK38L, MBP, RIPK1, ECT2, RAB6A, MARK2, EIF2AK3, IFT122, CNOT10, RAB27B, NFKB1, SETX, NFKBIA, CNOT6, IRAK1BP1, COL1A2, PTPRA, CNOT1, GNAQ, RCAN3, BCL3, NMUR1, CNOT8, CALM1, CALM2, BTG2, CDKN1A, MCTP1, PRKCSH, MAST3, DOCK8, BBC3, POLB, FLCN, AKAP13, AKAP11, NKIRAS1, C1QBP, CASP2, CTSH, RAB8B, CCR2, KSR1, SPHK1, OXSR1, TMEM173, GFRA2, SPTB, SIRT2, VAV1, GAL, ALS2, TFDP2, TAX1BP3, PIK3C3, LCP2, LCP1, DOCK2, ARHGEF5, EXOC1, HBEGF, ROCK2, TANK, RELA, RAB21, PPP2CA, GNG2, RAB20, PABPN1, CCL5, TIFA, MKNK2, NCAM1, ZNF622, BID, E2F7, E2F8, MAP3K3, CCL20, TSHR, RAB11A, SNRK, ITCH, TNIP2, CAMK4, RAB18, CCM2, KRAS, CAMK1]
GO:2000630;positive regulation of miRNA metabolic process;8.0;0.9326813400603323;0.8413406700301662;9.57973408832269;378.4717563008913;8.16763571524637;0.012667109080923946;0.7926932703116032;[NFKB1, RELA]
GO:0050710;negative regulation of cytokine secretion;9.0;0.6954798709641801;0.743980560662379;9.089527751759436;549.9868642983072;5.734022359845919;0.01840756539202174;0.6894787953221185;[NLRP12, PPP1R11, NLRP7, NLRP3]
GO:0010390;histone monoubiquitination;11.0;0.8933024483968273;0.8790801765280758;9.589303539338841;498.95626046972137;6.375876246018314;0.016699617006440744;0.7584915600596062;[DDB1, RNF20, DTX3L]
GO:0050728;negative regulation of inflammatory response;7.0;0.6729672293956388;0.6874029799550199;8.712233520617966;126.17514047852296;5.085725745451326;0.004222968401562039;0.6110036163900148;[BCR, ABR, NLRP12, CUEDC2, NLRP7, NLRP3, RORA, NFKB1, IL22RA2]
GO:0060998;regulation of dendritic spine development;10.0;0.8259837884571596;0.8282329060895002;9.517298617381897;87.62706980140223;5.572381008289503;0.002932799167010087;0.7002128357670632;[FXR1, ACTR2, CFL1, CAMK1, LRP8, PAFAH1B1]
GO:1902961;positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process;11.0;1.0;0.9324289523296623;9.628524252492122;1348.57412674769;7.9853141584524145;0.04513556238432715;0.8407982897480031;[ROCK2]
GO:0000226;microtubule cytoskeleton organization;5.0;0.579397892394798;0.5799399580583193;7.662411396119289;30.307791186580253;3.8212362582156385;0.0010143744957736317;0.4856592118117268;[SPAG16, HDAC3, TUBGCP2, CIB1, TUBA1C, SPAST, KIF19, NUF2, LMNA, FBXO5, CLASP1, MARK2, BBS2, UBE2B, CKAP5, IQCG, NDC80, RAB11A, NSFL1C, NIN, SON, ESPL1, FES, TBCE, VAMP4, CALM1, MAPRE1, KPNB1, PAFAH1B1]
GO:1902966;positive regulation of protein localization to early endosome;8.0;1.0;0.875;9.628524252492122;104.26631903438536;7.9853141584524145;0.00348969986448594;0.7833693374183408;[DTX3L, ROCK2]
GO:0002764;immune response-regulating signaling pathway;5.0;0.5860072649471136;0.5832446443344771;7.893923197104016;48.795248251786205;3.532906727016733;0.0016331330461149228;0.4709140261775204;[COLEC12, NCKAP1, WIPF2, ITGB2, ARPC1A, LILRA2, TANK, RELA, EP300, CTSH, NCKAP1L, RIPK1, CSK, HLA-DQA1, HLA-DPA1, FGA, ACTR2, CREBBP, FCER1G, BTN2A1, FGG, TMEM173, NFKB1, VAV1, NFKBIA, ITCH, CD4, ARPC2, TNIP2, ELMO1, HLA-DPB1, MNDA, PIK3C3, LCP2, KRAS, CALM1, HLA-DRB3]
GO:0019076;viral release from host cell;7.0;0.8436909121759173;0.7727648213451592;9.387362195675234;33.814119637874356;7.9853141584524145;0.001131728153547711;0.7592887026755414;[PPID]
GO:0000470;maturation of LSU-rRNA;10.0;0.8436909121759173;0.837086467948879;9.446202695698167;358.78453946307087;6.558197802812269;0.012008195650706942;0.7506275524841266;[WDR37, LAS1L]
GO:0070431;nucleotide-binding oligomerization domain containing 2 signaling pathway;13.0;1.0;0.9625549647676366;9.628524252492122;488.61025226297863;7.8311634786251565;0.01635334542256394;0.8630410292508717;[NFKBIA, RELA]
GO:0045022;early endosome to late endosome transport;6.0;1.0;0.8231203125901445;9.628524252492122;50.18376484494501;6.686031174322154;0.001679605446904144;0.665044257777226;[BECN1, PIK3C3]
GO:0030098;lymphocyte differentiation;5.0;0.6144040707577935;0.597443047239817;8.242229891372231;42.30537076970773;4.498958968449952;0.001415922687300292;0.5203179827304387;[CMTM7, DCLRE1C, FCER1G, FLT3LG, RORA, IKZF1, RUNX2, VAV1, DOCK11, CD4, SP3, BCL3, EP300, ATP7A]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[CUEDC2, SUCNR1, CFH, OTUD7B, RORA, RELA, C2, IL22RA2, C3, ABR, NLRP7, C1QBP, CCL5, NPPA, NLRP3, A2M, CCR2, FCER1G, ITGA2, NFKB1, BCR, NFKBIA, NLRP12, IL6, KARS, IL23A, MGLL, C1QC]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[COLEC12, ERRFI1, ACTR2, ABCC2, IGFBP5, ROCK2, ITGA2, ITPR2, RORA, TMEM173, LRP8, ELK1, SIRT2, NFKB1, UBE2L3, NFKBIA, RAP1B, SFRP1, GNG2, XRN1, CCL5, DDIT4, RAE1, EZH2]
GO:0035666;TRIF-dependent toll-like receptor signaling pathway;13.0;0.9326813400603323;0.9288956347978027;9.592156608321247;413.3481394832653;6.599019797332524;0.013834390239330937;0.8000291440890255;[RIPK1, TANK]
GO:0010389;regulation of G2/M transition of mitotic cell cycle;8.0;0.7369933605727446;0.7434966802863723;8.986670366319727;58.92720908338202;4.74012102526684;0.001972240656975688;0.6174100096703167;[FANCI, CENPF, GPR132, RAD51C, PKIA, RAD21, CEP70, MAPRE1, CKAP5, CLASP1, RAB11A, PAFAH1B1]
GO:0031060;regulation of histone methylation;9.0;0.6441938053840475;0.7183375278723128;9.027750392063192;102.09780493635188;5.587418885654044;0.003417121649160743;0.6819814868341874;[RNF20, ZNF462, GFI1, ZNF407, MTF2, SUPT6H]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[CDKN1C, BECN1, BTG2, CDKN1A, CD80, LST1, SIRPG, CIB1, COMT, THBS1, STK3, FLCN, ADORA3, RPS6KA2, FNTB, NUP62, TP53INP1, LMNA, TRIM24, CSK, RBM5, E2F7, TFAP2A, KLF13, IGFBP5, ATPIF1, IDH2, GLMN, IFT122, EMP3, PDCD1LG2, SIRT2, PER2, ITCH, SFRP1, TWSG1, IL6, GAL, KARS, FAP, NFIB, CD9, TAX1BP3, MNDA, CNOT8, TRIM32]
GO:0031062;positive regulation of histone methylation;10.0;0.7508913569872202;0.7906866903545304;9.430698509162202;696.97466704471;6.221725566191056;0.023327114869509745;0.7334203466557586;[RNF20, MTF2]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[CDKN1A, WDR48, TFRC, ITGB3, CD80, SIRPG, CCNF, CIB1, TIAL1, PPP1CC, LBH, FNTB, CTSH, SOX8, ATP7A, SKP2, CCR2, HLA-DPA1, RPS9, TIPIN, CSNK2A1, IGFBP5, SPHK2, ITGA2, SPHK1, TBC1D8, ARNT, FLT3LG, PDCD1LG2, RUNX2, ERN1, SFRP1, IL23A, EPHA1, HBEGF, HDAC1, FOXG1, DERL2, CRIP2, THBS1, RELA, HLA-DMB, CCL5, NCKAP1L, CCL19, TBX1, MAP3K3, TSHR, CNOT6, CD4, IL6, SP1, HLA-DPB1, KRAS, CNOT8, CCNJL]
GO:0060307;regulation of ventricular cardiac muscle cell membrane repolarization;9.0;0.811012628672052;0.801746939516315;9.474373572664863;48.25689803028158;6.781341354126479;0.001615114948684907;0.7430387373949403;[WDR1]
GO:1901522;positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus;12.0;0.7140352122741334;0.8051379187272112;9.260799472366804;1467.8987330058965;6.641579411751319;0.04912924957061573;0.7877709925721352;[CREB3, RXRA, EP300, RUNX2, RELA]
GO:1901888;regulation of cell junction assembly;5.0;0.7508913569872202;0.6656866903545304;8.935377071932177;27.318252308649967;5.370354380416217;9.14317319939619E-4;0.5648811846224242;[RAP1B, SFRP1, ROCK2, THBS1, CLASP1, LIMS1]
GO:0060545;positive regulation of necroptotic process;7.0;1.0;0.8509193652572005;9.628524252492122;151.94543820684703;9.083926447120524;0.005085477074766827;0.8154717862087246;[RIPK1]
GO:2000659;regulation of interleukin-1-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.446202695698167;58.00234281560482;7.8311634786251565;0.001941286215318787;0.7514054297404357;[IL6, VRK2]
GO:0071550;death-inducing signaling complex assembly;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;40.42272244673708;7.697632086000634;0.0013529121422039536;0.6838982747154925;[RIPK1]
GO:0070588;calcium ion transmembrane transport;9.0;0.7140352122741334;0.7532582313173557;9.078477915572849;116.6808485568922;4.562137870071484;0.003905202995253044;0.629548568016852;[CACNA2D3, ITPR2, PKD2L1, CCL19, TRPC4AP]
GO:2000774;positive regulation of cellular senescence;7.0;1.0;0.8509193652572005;9.628524252492122;164.05173707047635;7.474488534686424;0.005490664002770884;0.7331650565203278;[KRAS]
GO:0032147;activation of protein kinase activity;11.0;0.6799073451904818;0.7723826249249031;9.164951513576677;1096.8683293671154;4.034070439870987;0.03671119586651001;0.6387315022281249;[MAP3K3, PDE6H, ITGB3, ZFP91, TNFRSF10A, PILRB, OXSR1, THBS1, STK3, ERN1, KARS, NCKAP1L, RIPK1, ADNP, CCL19, ECT2, MARK2]
GO:0033234;negative regulation of protein sumoylation;10.0;0.9326813400603323;0.8815816818910864;9.587702257971866;528.6159484410776;7.379178354882098;0.017692300070855854;0.7926125360964777;[GNL3L, RELA]
GO:0010595;positive regulation of endothelial cell migration;9.0;0.8259837884571596;0.8092325194088689;9.488762310116963;298.6320589889849;5.2552850506314295;0.009994946262957053;0.664996147065328;[MAP3K3, SP1, ROCK2, ITGB3, CIB1, THBS1]
GO:0032269;negative regulation of cellular protein metabolic process;7.0;0.4739867211454891;0.587912725829945;7.449991808168055;289.3917989888356;2.854429736204582;0.009685683076446155;0.4968950347112605;[CDKN1C, ERRFI1, SERPINA3, BTG2, CDKN1A, PPP1R11, SERPINA10, CIB1, UBE2Z, DUSP14, EIF4ENIF1, FLCN, NUP62, PHACTR2, FBXO5, DACT1, UPF1, SERPINB1, CSNK2A1, IGFBP5, DTX3L, PLAUR, SENP2, SIRT2, SERPINB6, ILF3, SFRP1, XRN1, CTDSP2, MTF2, DDIT4, EIF4E2, EPHA1, CHMP6, PAFAH1B1, CSTB, CSTA, HDAC3, ITIH2, ROCK2, CLEC16A, DERL2, NLRC4, SUPT6H, THBS1, GLG1, RELA, C3, FXR1, PPP2CA, U2AF2, NLRP7, SNX25, TPR, STK38, NCKAP1L, CSK, LRIG2, RFFL, A2M, UBE2B, AMBP, YTHDF3, GLMN, EIF2AK3, CNOT10, TNFRSF10A, NFKB1, VIL1, PER2, ITCH, NLRP12, GNL3L, CNOT1, GNAQ, PKIA, TAF7, CNOT8, CALM1, CALM2, MAD2L1, CPEB4]
GO:0050852;T cell receptor signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;219.43154282413207;4.981283082083729;0.007344176262756358;0.6699840603320352;[CD4, BTN2A1, HLA-DPB1, LCP2, CSK, HLA-DRB3, HLA-DQA1, NFKB1, RELA, HLA-DPA1]
GO:0071316;cellular response to nicotine;5.0;1.0;0.7902410118609202;9.628524252492122;116.90797783109151;7.697632086000634;0.003912804807657419;0.6838982747154925;[NFKB1, RELA]
GO:0033590;response to cobalamin;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;87.04156493882871;8.390779266560578;0.002913202846179917;0.7800242071602487;[RELA]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[CD80, CSK, PDCD1, PDCD1LG2, CCL19, VAV1]
GO:0031293;membrane protein intracellular domain proteolysis;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;50.748517158788495;6.8867018697843045;0.0016985071986044009;0.7031056191423581;[NFKB1, RELA]
GO:0000209;protein polyubiquitination;10.0;0.7671156992804218;0.7987988615011312;9.223059144383958;155.4032479663248;4.243684138952949;0.005201206855589802;0.6322632160784685;[RNF20, UBE2B, DTX3L, CCNF, SYVN1, ZFP91, FBXL15, LNPEP, FBXL16, ANAPC11, UBE2L3, NPEPPS, ITCH, RNF213, UBE2T, CDC26, TRIM69, FBXL3, ANAPC5, RFFL, SKP2, C18orf25, TRIM32]
GO:0048666;neuron development;4.0;0.6696747006330769;0.5848373503165385;8.088079211544972;32.15320660831846;4.814228997420562;0.001076138889173156;0.4961998948126311;[FXR1, BECN1, BTG2, ONECUT2, GNAT2, UQCRQ, GNAQ, PBX3, THOC2, ATP7A, PAFAH1B1]
GO:0009267;cellular response to starvation;6.0;0.6369964171292115;0.6416185211547503;8.460919092337061;112.76702064936369;4.807260328104469;0.0037742106974044997;0.5689638293298743;[BECN1, GABARAPL1, CDKN1A, SEH1L, MAX, CLEC16A, EIF2AK3, COMT, SFRP1, TBL2, MARS, LAMP2, PIK3C3, FADS1, CPEB4]
GO:0061621;canonical glycolysis;15.0;1.0;0.9883613244510648;9.628524252492122;17318.20443184688;6.558197802812269;0.5796247169618144;0.8237478650742711;[HK3, TPI1, ADPGK, BPGM, ALDOA]
GO:0090160;Golgi to lysosome transport;8.0;1.0;0.875;9.628524252492122;114.4124755644324;7.697632086000634;0.0038292825925985686;0.7686572628545723;[AP1G1]
GO:0050862;positive regulation of T cell receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;365.0896954818653;7.212124270218933;0.01221922354838398;0.7438283705770736;[RELA]
GO:0048791;calcium ion-regulated exocytosis of neurotransmitter;10.0;0.8933024483968273;0.861892236059334;9.551563211355994;176.6280078189881;6.343086423195323;0.005911580466814719;0.7396267465268138;[SYTL3]
GO:1990830;cellular response to leukemia inhibitory factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[TLE4, TFRC, XRCC5, MTF2, ADAM23, BSPRY]
GO:0035646;endosome to melanosome transport;6.0;1.0;0.8231203125901445;9.628524252492122;33.20429938101479;7.474488534686424;0.0011113180183532213;0.7053660038532718;[AP1G1]
GO:0034314;Arp2/3 complex-mediated actin nucleation;13.0;1.0;0.9625549647676366;9.628524252492122;481.965084327204;6.599019797332524;0.016130937632016437;0.8000291440890255;[ACTR2, ARPC2, ARPC1A, IQGAP2]
GO:2000786;positive regulation of autophagosome assembly;9.0;1.0;0.896240625180289;9.628524252492122;594.8628679994155;7.379178354882098;0.019909524850116572;0.7736121494158466;[BECN1, RAB3GAP2, RAB3GAP1]
GO:0032496;response to lipopolysaccharide;5.0;0.8933024483968273;0.736892236059334;9.446202695698167;64.414971589946;4.086714173356409;0.002155911129404774;0.4992357647380114;[UPF1, ABCC2, CCL20, GFI1, CD80, TNFRSF10A, PDCD1LG2, COMT, NFKB1, RELA, BCR, ABR, IL6, PABPN1, NLRP7, TBXA2R, TNIP2, NLRP3]
GO:0032375;negative regulation of cholesterol transport;8.0;0.7980440201809971;0.7740220100904985;9.271849308553389;149.42902716417655;7.292166977892469;0.005001255061791553;0.747921758369865;[NFKB1]
GO:0015813;L-glutamate transmembrane transport;11.0;0.8653626801206646;0.8651102923899945;9.551563211355994;441.01685901872065;6.8867018697843045;0.014760437381951706;0.7846152062148197;[ARL6IP5, NTSR1]
GO:0071549;cellular response to dexamethasone stimulus;9.0;1.0;0.896240625180289;9.628524252492122;704.2721689024621;6.343086423195323;0.023571355689363423;0.7206263598461826;[ERRFI1, ABCC2, DDIT4]
GO:0007080;mitotic metaphase plate congression;7.0;1.0;0.8509193652572005;9.628524252492122;61.63195576956532;6.193554689224359;0.002062766094448262;0.6676580400938822;[BECN1, SEH1L, NUP62, CDCA8, CHMP4B, CHMP6, KPNB1, RAB11A]
GO:2000301;negative regulation of synaptic vesicle exocytosis;11.0;0.8653626801206646;0.8651102923899945;9.556203590912496;1062.0365534281786;8.67846133901236;0.03554540767239695;0.8762458687964789;[RAP1B]
GO:0048713;regulation of oligodendrocyte differentiation;9.0;0.8933024483968273;0.8428918493787028;9.485423408851448;65.83981520803086;6.311337724880743;0.0022035993630260702;0.7190027299379095;[WDR1, ZNF365]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[MAP3K3, SMG1, CAD, EIF2AK3, VRK2, CLK4, CLK3, CLK1, ERN1, BCR, FES, CAMK4, MKNK2, TRIM24, RIPK1, CSK, EPHA1, MARK2]
GO:0042177;negative regulation of protein catabolic process;7.0;0.7140352122741334;0.7079369713942671;9.105276108727574;231.8232476428224;5.040875179285974;0.007758915471227624;0.6087099563505541;[CLEC16A, DERL2, LRIG2, SIRT2, RELA, MAD2L1]
GO:0045444;fat cell differentiation;4.0;0.8653626801206646;0.6826813400603323;9.292052015870908;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[BBS2, PER2, NIPBL, TBL1XR1, FAM120B, EP300, SOX8, OSBPL11, SENP2, TRIM32]
GO:0032091;negative regulation of protein binding;5.0;0.6997970393407541;0.6401395315312973;8.48339194818912;32.716075545242866;5.171903441692378;0.0010949776059428606;0.5547323943871747;[GNL3L, TFIP11, CAMK1, ADNP, SENP2, DACT1]
GO:0023014;signal transduction by protein phosphorylation;8.0;0.7248374789738407;0.7374187394869203;9.153100555777048;203.92357026499027;3.9689311377000256;0.006825138377471068;0.5779713229561524;[MAP3K3, OXTR, KSR1, IL5RA, OXSR1, GFRA2, SPTB, RASGRP4, NFKB1, STK3, SETX, KARS, PABPN1, PTPRA, TNIP2, CCL5, CTSH, NCAM1, CCM2, MBP, RIPK1, KRAS, CALM1, HBEGF]
GO:0060964;regulation of gene silencing by miRNA;8.0;0.7369933605727446;0.7434966802863723;9.158520623246385;63.198578554006836;5.8067817141283475;0.0021151995491745495;0.6719590869034888;[FXR1, IPO8, POLR2B, H3F3A, POLR2G]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[VIL1, CSNK2A1, PLAUR, TNFRSF10A, NLRC4, RFFL, UBE2Z, THBS1]
GO:0043032;positive regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.59742726208806;6.641579411751319;0.004237101960174532;0.6905700452391912;[IL4R, KARS, TNIP2, ITGB2, THBS1]
GO:0006919;activation of cysteine-type endopeptidase activity involved in apoptotic process;13.0;0.9326813400603323;0.9288956347978027;9.604426700913061;734.4853933519539;5.322726331426962;0.024582565121551242;0.7347594368888992;[NLRP12, DIABLO, EIF2AK3, NLRP3, CTSH, RIPK1, TNFRSF10A, NLRC4, BID, HSPE1, BBC3]
GO:0055007;cardiac muscle cell differentiation;6.0;0.7866048967936545;0.7164227609869718;9.0689084645567;45.916641199513585;6.409777797693995;0.0015367886586535107;0.6509166472493662;[AKAP13, RXRA, ARID1A]
GO:0035357;peroxisome proliferator activated receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;25.568165535828406;7.697632086000634;8.557434906291208E-4;0.7167775754447168;[RXRA, FAM120B]
GO:2000553;positive regulation of T-helper 2 cell cytokine production;10.0;1.0;0.9152410118609203;9.628524252492122;874.8811381751227;7.9853141584524145;0.029281484352815565;0.8236103492792612;[IL6, NLRP3]
GO:0032088;negative regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.61713652769816;5.420364800990877;0.009358533920496976;0.725318020585559;[NFKBIA, ITCH, NLRP12, ADORA3, GFI1, NLRP3]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[SFRP1, TBL1XR1, NFKB1, ARNTL, DACT1]
GO:1900740;positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway;10.0;1.0;0.9152410118609203;9.628524252492122;990.0589542238915;6.599019797332524;0.033136382202663156;0.7527151911823093;[TFDP2, TP53BP2, BID, YWHAZ, BBC3]
GO:0045214;sarcomere organization;7.0;1.0;0.8509193652572005;9.628524252492122;33.95844942788184;6.063501560976162;0.0011365587417308835;0.6610071170671804;[WDR1]
GO:0043278;response to morphine;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;93.3430750065417;6.280566066213989;0.0031241087171554015;0.6721078059595746;[RELA]
GO:0043280;positive regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.811012628672052;0.8536266269261705;9.556203590912496;733.386781063286;4.956792062075433;0.024545795556936395;0.7016108891590862;[NLRP12, DIABLO, EIF2AK3, ARL6IP5, NLRP3, CTSH, RIPK1, TNFRSF10A, NLRC4, BID, HSPE1, BBC3]
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;9.0;0.7586651285174919;0.775573189439035;9.310070521373587;348.3589749790861;4.015022244900292;0.01165926138982685;0.6015690495021188;[RNF38, CCNF, DERL2, PSMB10, PSMA7, ANAPC11, ARNTL, PSMD8, TRIM9, PSMD7, PSMD4, PSMD2, CDC26, PSMB1, UBQLN1, RFFL, SKP2, C18orf25, UBE2I, LRRC29, UBE2B, FBXO18, EDEM1, SYVN1, FBXL15, RAD23A, ERLIN2, FBXL16, KCTD5, SIRT2, DDB1, KBTBD4, NSFL1C, ITCH, PSMA1, KCTD10, TBL1XR1, PSMC1, FBXL3, ANAPC5, MAN1B1, MAD2L1]
GO:0000390;spliceosomal complex disassembly;6.0;1.0;0.8231203125901445;9.628524252492122;58.04709595168642;8.390779266560578;0.0019427840625082307;0.7522251544931926;[TFIP11]
GO:0034138;toll-like receptor 3 signaling pathway;12.0;1.0;0.9481203125901445;9.628524252492122;412.6549923027037;7.474488534686424;0.013811191226989502;0.8303660038532719;[COLEC12, TNIP2, RIPK1]
GO:2000321;positive regulation of T-helper 17 cell differentiation;13.0;0.9326813400603323;0.9288956347978027;9.611994950540911;2604.3016792955605;7.697632086000634;0.08716363348667819;0.8562122276222088;[IL23A, NLRP3]
GO:0034498;early endosome to Golgi transport;7.0;1.0;0.8509193652572005;9.628524252492122;101.51493214272642;7.57984905034425;0.0033976134213095565;0.738553198190834;[STX5, RAB6A]
GO:0008089;anterograde axonal transport;9.0;0.8259837884571596;0.8092325194088689;9.405380701177911;71.1020239957658;6.113511981550823;0.0023797207554711163;0.7088859122241795;[RAB21, FXR1, AP3M1, SPAST, TRAK1]
GO:0034497;protein localization to phagophore assembly site;5.0;1.0;0.7902410118609202;9.628524252492122;29.829169826127035;7.212124270218933;9.983554695705216E-4;0.659069382437994;[PIK3C3]
GO:0034134;toll-like receptor 2 signaling pathway;12.0;0.9326813400603323;0.9144609826203107;9.590783924509275;412.6549923027037;8.16763571524637;0.013811191226989502;0.8658135829017477;[TNIP2]
GO:0045104;intermediate filament cytoskeleton organization;5.0;0.8259837884571596;0.7032329060895001;9.271849308553389;28.228349644899765;5.926926025970411;9.447774587494734E-4;0.5933442844592942;[TOR1A]
GO:0044257;cellular protein catabolic process;6.0;0.7763722522362496;0.7113064387082693;9.277126365654233;323.3351550789029;6.193554689224359;0.01082173665774351;0.6398589874268261;[LAMP2, CLTA, RIPK1]
GO:0060627;regulation of vesicle-mediated transport;5.0;0.4849414530207067;0.5327117383712736;6.805163204878917;26.124861613659725;3.5745381104925467;8.743756073601922E-4;0.47304305706453076;[RAB3B, MCTP1, C12orf4, ITGB2, SIRPG, STON1, TRIM9, AP1G1, NPPA, EVI5L, TBC1D22A, RAB8B, CCR2, VPS18, FGA, PDCD6IP, IL4R, FCER1G, ITGA2, FGG, TBC1D8, UNC13D, SYTL3, BCR, RUFY1, DOCK2, RABGAP1, CD151, GOSR1, C2, RAB21, C3, RAP1B, ABR, ATXN2, RAB20, VPS11, NCKAP1L, CSK, CCL19, CLASP1, VPS16, TOR1A, RAB27B, RAB11A, SYNJ1, SNX17, FES, VPS41, SDC1, PTX3, RAB3GAP1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[CIITA, BTG2, GFI1, OTUD7B, IKZF2, YY1, FLCN, NIPBL, C1QBP, SAP130, WWC3, EP300, SOX8, LRRFIP1, HIF1AN, ZNF564, DACT1, TLE4, KLF12, PEG3, ARID1A, SIRT2, EID1, TBL1XR1, MTF2, HOXB4, TIMELESS, LCOR, PPID, HDAC3, ZNF350, HDAC1, MAX, FOXG1, LRP8, RELA, RXRA, BAG3, TPR, HIVEP1, HESX1, SUDS3, E2F7, ZNF189, E2F8, IRX1, TFAP2A, DR1, CREBBP, UBE2I, NFKB1, PER2, GFI1B, CNOT1, NFIB, NFIC, PKIA, SP3, NFE2L3, TAF7, EZH2]
GO:0045471;response to ethanol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;69.73224034292265;5.006389003214805;0.0023338753293357085;0.5462679783062231;[POLB, ACTR2, TBXA2R, TP53INP1, ITPR2]
GO:0043171;peptide catabolic process;6.0;0.7192862368539868;0.682763431017138;8.971744716103052;139.83704318034597;6.280566066213989;0.0046802199900778775;0.6443087532925187;[NPEPPS, XPNPEP1, CTSH, LNPEP, TPP1]
GO:1901838;positive regulation of transcription of nucleolar large rRNA by RNA polymerase I;12.0;1.0;0.9481203125901445;9.628524252492122;1713.7225603957397;7.474488534686424;0.05735675184627241;0.8303660038532719;[MARS]
GO:0045595;regulation of cell differentiation;4.0;0.3376379861120121;0.41881899305600606;5.249000748036359;23.33457331431992;2.3564947222696686;7.809871690777242E-4;0.3705112496850823;[ERRFI1, PLEKHB2, MAML1, GFI1, CD80, PLEKHB1, CIB1, RORA, CYB5D2, EIF4ENIF1, PPP1CC, KIAA1109, CFL1, EP300, SOX8, FADS1, SEMA6B, IL4R, IGFBP5, FLT3LG, THOC2, UNC13D, RUNX2, OLFM1, EID1, SFRP1, TWSG1, IL23A, RUFY3, HOXB4, ADNP, ANKRD17, FOXG1, SUPT6H, GLG1, STK3, FXR1, DVL3, NLRP3, NCKAP1L, RIPK1, ECT2, MARK2, TFAP2A, CREBBP, XRCC5, H3F3A, IDH2, SSH3, NFKB1, SETX, CDK9, NFKBIA, IL6, SYNJ1, ARPC2, COL5A1, FES, GNAQ, MAFF, EZH2, WDR1, ITGB3, FLCN, AKAP13, NIPBL, LBH, C1QBP, HIF1AN, SCARF1, ZNF365, CCR2, FGA, ACTR2, KLF13, FGG, ARNT, SIRT2, MED28, GAL, PAFAH1B1, HEMGN, HDAC1, ROCK2, TRAK1, LRP8, THBS1, RELA, ARNTL, RAB21, PPP2CA, RBBP5, TP53INP1, LRIG2, CCL19, CLASP1, TBX1, TMEM30A, TMEM176A, GRHL1, LILRB3, RAB11A, PER2, ITCH, CD4, CAMK4, KRAS, CAMK1, TRIM32, C1QC, LIMS1]
GO:0045596;negative regulation of cell differentiation;5.0;0.44223782556504454;0.5113599246434426;6.502738850689933;82.78823984741369;3.2727854541438237;0.0027708478831143203;0.4576114121859235;[ANKRD17, ITGB3, FOXG1, GFI1, CIB1, RORA, ARNTL, PPP2CA, EIF4ENIF1, LBH, TP53INP1, SOX8, LRIG2, ZNF365, TBX1, SEMA6B, IL4R, KLF13, IGFBP5, TMEM176A, IDH2, THOC2, LILRB3, SIRT2, MED28, NFKBIA, SFRP1, TWSG1, IL6, GAL, COL5A1, RUFY3, KRAS, PAFAH1B1, C1QC, EZH2]
GO:0043297;apical junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;56.140948375987016;7.697632086000634;0.001878987018571015;0.7167775754447168;[WDR1]
GO:1990502;dense core granule maturation;7.0;1.0;0.8509193652572005;9.628524252492122;31.399434805935044;8.67846133901236;0.001050910825297963;0.7947362817240173;[SNX19]
GO:0070301;cellular response to hydrogen peroxide;6.0;1.0;0.8231203125901445;9.628524252492122;361.02555909653125;5.682729065458369;0.012083200561052132;0.6137353412716126;[SETX, BECN1, IL6, ECT2, RELA, EZH2]
GO:0050708;regulation of protein secretion;7.0;0.544374901031353;0.623106815772877;7.862740269667327;96.15283043706451;3.7392027077583316;0.003218148702799284;0.5421423656226702;[FGA, IL4R, PPP1R11, RHBDF2, IDH2, FGG, GLMN, ITPR2, ARNTL, PER2, NLRP12, SFRP1, IL6, KARS, NLRP7, CCL5, NLRP3, MBP, ARFIP1, PIK3C3, CCL19, CD244, PPID, EXOC1]
GO:0035690;cellular response to drug;4.0;0.5629771490299041;0.531488574514952;7.020557509946895;41.90713853914268;4.145861845859104;0.0014025942129290189;0.462019567599527;[BECN1, ERRFI1, ABCC2, TFRC, CAD, ITPR2, NFKB1, RELA, EFTUD2, SETX, RAP1B, SFRP1, IL6, XRN1, TP53INP1, DDIT4, TIMELESS, ECT2, EZH2]
GO:0031098;stress-activated protein kinase signaling cascade;6.0;0.7980440201809971;0.722142322680643;9.193206181234276;55.4262366053078;5.142344639450834;0.0018550662588052154;0.5861000565951415;[MAP3K3, TNIP2, CCM2, OXSR1, NFKB1, STK3]
GO:0044267;cellular protein metabolic process;5.0;0.3358520568840654;0.45816704030295297;5.574370570853267;80.86766357206795;1.6585685600933726;0.0027065679235849286;0.3750602851554211;[OXTR, RPL3, MAML1, CCNF, ZDHHC5, UBE2L3, PSMD8, HERC4, PSMD7, HERC1, PSMD4, RPL36AL, RPS6KA2, PSMD2, CDC26, TRIM24, SKP2, CSNK2A1, COG3, MRPS18A, PRKAB1, BCR, KARS, KCTD10, PSME2, EPHA1, FUT11, ANAPC11, C3, TGOLN2, NUAK1, RHOT1, RNF213, HLTF, STK38L, CREBBP, ABCA3, EDEM1, H3F3A, EIF2AK3, LNPEP, ERLIN2, PGA3, RPL3L, PGA5, SETX, FBXL3, CALM1, EZH2, CPEB4, PIGS, HBS1L, BTG2, SMG1, WDR48, PPP1R11, SERPINA10, CLTA, OTUD7B, TRIM9, AKAP13, ZMYM2, CTSH, PCMTD1, VKORC1, MRPS24, JOSD1, GFRA2, SIRT2, DDB1, PSMA1, PDIK1L, FASTKD5, HBEGF, CSTA, MRPS36, ZDHHC23, ZDHHC24, DERL2, NEDD8, TRAK1, PSMA7, PPP2CA, GGA3, PSMB1, APOL1, RPL19, MAP3K3, SYVN1, GTF2H4, RAB11A, PER2, ITCH, CAMK4, PSMC1, KBTBD2, CAMK1, RAB3B, GALNT12, ARID4A, IL5RA, STK19, UBE2Z, GALNT10, YY1, PPP1CB, PPP1CC, NPEPPS, FNTB, NPPA, LAMP2, CFL1, EP300, TGM6, C18orf25, RPS9, FBXO18, IGFBP5, VPS33B, SSU72, VRK2, TRPC4AP, ERN1, DPM3, ILF3, TBL1XR1, ANAPC5, PPID, HIST1H2BC, UBR4, DTX2, KLHL12, RLF, RASGRP4, FUT4, STK3, VCPIP1, STK35, UBD, STK38, NLRP3, USP51, MBP, RIPK1, SUDS3, RAB6A, MARK2, DR1, UBE2I, TOR1A, UBE2B, KLHL25, AMBP, DOLK, CLK4, SSH3, CLK3, NFKB1, CLK1, CDK9, NFKBIA, IL6, PAN3, COPS5, PTPRA, MAN2B2, FES, UBE2T, USP36, PRKCSH, MAST3, USP32, USP39, MSLN, DUSP14, SENP6, POLB, PPP6C, SUMO3, TRIM69, HIF1AN, ATP7A, USP46, FGA, KSR1, DTX3L, FGG, CAD, ZFP91, DUSP28, RAD23A, OXSR1, SENP2, SPTB, PTP4A1, DUSP23, CTDSP2, PIK3C3, ETF1, MAN1B1, USP41, BECN1, HDAC3, HIST1H2BO, ITIH2, HIST1H2BJ, HDAC1, ROCK2, RNF38, USP12, RRBP1, NLRC4, THBS1, PSMB10, PPM1G, PABPN1, RBBP5, CCL5, MKNK2, NCAM1, CSK, RFFL, SEC11A, RNF20, NDUFA7, EYA2, FBXL15, RPL23A, FBXL16, POLE4, SNRK, TNIP2, TSPAN17, CCM2, KRAS, TRIM32]
GO:0000244;spliceosomal tri-snRNP complex assembly;8.0;1.0;0.875;9.628524252492122;66.59596265062147;7.292166977892469;0.002228906937441061;0.747921758369865;[PRPF3, CD2BP2]
GO:0002674;negative regulation of acute inflammatory response;8.0;0.7369933605727446;0.7434966802863723;9.132087366178231;164.84175655116067;7.292166977892469;0.005517105243818016;0.747921758369865;[NLRP3]
GO:0006906;vesicle fusion;6.0;0.6799073451904818;0.6630739851853854;8.563813515499694;63.097974703971886;5.192106149009898;0.0021118324288514666;0.5886448625081389;[GOSR1, STX11, SYTL3, TAPBP, RAB20, VPS41, VPS8, VPS11, STX5, SNAP29, SPG11, VAMP5, RAB8B]
GO:0048873;homeostasis of number of cells within a tissue;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;26.75021374699733;6.444869117505266;8.953055804826206E-4;0.6527112189764278;[FLT3LG, KRAS, CCR2]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AVEN, BTG2, CDKN1A, DOCK8, CIB1, AATF, UBE2Z, NUP62, CFL1, CASP2, CTSH, SOX8, TSC22D4, FGA, DFFA, FCER1G, CSNK2A1, SPHK2, SPHK1, FGG, PLAUR, FLT3LG, YWHAZ, DDB1, CREB3, SFRP1, CFDP1, PTRH2, VDAC2, ADNP, EPHA1, PPID, BECN1, HDAC3, HDAC1, NLRC4, THBS1, RELA, BAG3, CCL5, LMNA, NCKAP1L, RIPK1, CCL19, RFFL, SNCB, BID, NTSR1, TBX1, TFAP2A, UBE2B, EYA2, SYVN1, TNFRSF10A, NFKB1, SETX, VIL1, NFKBIA, ITCH, IL6, SON, COPS5, TNIP2, BCL3, KRAS, PDCD1, TRIM32, MAD2L1, CPEB4]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[HRK, UBE2Z, BBC3, FLCN, AKAP13, RPS6KA2, C1QBP, ARL6IP5, CASP2, CTSH, RBM5, DFFA, FBXO18, ATPIF1, PLAUR, YWHAZ, SIRT2, VAV1, SFRP1, GAL, TFDP2, PTRH2, ARHGEF5, ITGB3BP, PPID, DIABLO, NLRC4, THBS1, STK3, ABR, CCL5, UBD, TP53INP1, TP53BP2, NLRP3, RIPK1, SUDS3, ZNF622, ECT2, BID, NTSR1, TFAP2A, EIF2AK3, G0S2, TNFRSF10A, HSPE1, NLRP12, IL6, FAP, MNDA, PDCD1, SERINC3]
GO:0034599;cellular response to oxidative stress;4.0;0.7248374789738407;0.6124187394869203;8.935377071932177;68.67201153720991;4.519578255652688;0.0022983904253524798;0.48113144217596127;[BECN1, NCF1, TXNRD1, GPX7, VRK2, SIRT2, RELA, SETX, IL6, PRDX1, TP53INP1, PXMP2, ECT2, NFE2L1, EZH2]
GO:0050823;peptide antigen stabilization;7.0;1.0;0.8509193652572005;9.628524252492122;60.01596331221528;9.777073627680469;0.0020086802811995464;0.8509193652572005;[TAPBP]
GO:0050701;interleukin-1 secretion;10.0;0.8933024483968273;0.861892236059334;9.523163736834295;137.06961104194002;7.474488534686424;0.004587596526932657;0.7974867031240476;[NLRP3, NLRC4]
